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ABSTRACT 
The high demand of novel peptide and peptidomimetics based on the amount of 
genomic and proteomic data need be matched by synthesis and screening. The design and 
synthesis of peptide and peptidomimetics are so important because the peptide and 
protein-protein interaction play a key role in molecule recognition and signaling. The 
modified peptides have better stability and pharmacokinetic properties which may be guided 
by rational design and molecular modeling. Now many organic and medicinal chemists have 
chosen peptide and peptidomimetics as potential drug candidates for many targets. 
In this dissertation, research efforts in design and synthesis of cyclic peptides with 
stabilized secondary structure have been investigated. Cyclization of linear peptides may 
restrict the number of available conformations which may improve the affinity attaching to 
the target. In this study, different beta turn linkers have been designed and synthesized to 
achieve more stable cyclic peptides with beta-sheet structures. Based on different beta turn 
linkers, analogs of cyclic peptides have been synthesized and screened. The structure activity 
relationships (SAR) of these cyclic peptide analogs have been studied.  
In chapter three, analogs of peptidomimetic inhibitors have been designed and 
synthesized. These peptide analogs are targetingHuman Rhinovirus (HRV) and Coronavirus 
(CoV) by inhibiting the cysteine protease. The docking and modeling studies have been 
shown. The structures of this kind of inhibitors include five fragments. The warhead provides 
 xii 
 
the activity, which can covalently react with the thiol of cysteine protease and permanently 
eliminate its proteolytic activity. The warhead is linked to a peptide backbone including the 
other four parts that are designed to position the warhead where it can specially react with the 
critical thiol of the cysteine protease active site. The side chain of each amino acid has been 
optimized to achieve better solubility and permeability. We successfully synthesized some 
compounds with good potency. 
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can be studied based on the structure similarity of the secondary structure elements. The 
prediction of binding site or protein interface can lead to the design of new drug candidates38, 
39. 
H2N COOH
S
Methionine
H2N COOH
Alanine
H2N COOH
Leucine
H2N COOH
COOH
Glutamic acid
H2N COOH
NH2
lysine
H2N COOH
NH
Tryptophan
H2N COOH
OH
Tyrosine
H2N COOH
Phenylalanine
H2N COOH
Valine
H2N COOH
HO
Threonine
H2N COOH
Isoleucine
Figure 1.7 Red structures are helix favored amino acids; blue are beta strand favored amino 
acids 
1.3 Peptide derivatives in Therapeutics Market 
In the drug discovery area, peptides are considered as a good candidate because of it is 
highly selective, effective, and relatively safe and well tolerated bioactivity40. More than 
7,000 natural peptides have been identified and they usually play important roles in human 
physiology. They may act as hormones, growth factors, ion channel ligands, or 
anti-infectives41, 42, 43. Normally, peptides can be very selectively and effectively bind to 
specific cell surface receptors where they can produce intracellular effects. Therefore, 
 8 
 
peptides have become an excellent starting point for the design of new therapeutics. This also 
makes peptides different from the traditional small molecules. So there is an increased 
interest in peptides for pharmaceutical R&D in recent years.  
During the past ten years, peptides have been investigated in a wide range of 
applications in medicine and biotechnology. Therapeutic peptide research is currently 
undergoing explosive growth for commercial reasons. Currently, there are more than 60 US 
Food and Drug Administration (FDA)-approved peptide medicines on the market For 
example, the peptide-based medicine LupronTM from Abbott Laboratories for the treatment of 
prostate cancer and more, achieved global sales of more than US$2.3 billion in 2011. 
LantusTM from Sanofi (which is at the border between a peptide drug and a small 
biopharmaceutical) reached sales of US$7.9 billion in 2013. Peptide based drug development 
is expected to grow significantly, with approximately 140 peptide drugs currently in clinical 
trials and more than 500 therapeutic peptides in preclinical trials. The market value of global 
peptide drugs is predicted to increase from US$14.1 billion in 2011 to an estimated US$25.4 
billion in 2018 (Figure 1.8).  
Although peptides are considered highly potent signal transduction molecules that exert 
powerful physiological effects, they are also recognized by weak spots like chemical and 
physical instability, easy hydrolysis and oxidation, tendency toward aggregation, short life 
and fast elimination, and low membrane permeability. To make them better drug candidates, 
traditional rational design of peptide therapeutics has focused on techniques to mitigate these 
weaknesses44, 45. 
 9 
 
 
Figure 1.8 Global Peptide Therapeutics Market revenue 
Peptides rational design ideally starts with a known NMR structure or a crystal structure 
of the peptide with the secondary and tertiary structure well defined. Then, various analyses 
are introduced, such as alanine substitutions and small focused libraries. The 
structure–activity relationship (SAR) is built which leads to the identification of the sequence 
of amino acids and also sites for possible substitution (Figure 1.9). Also, the design of 
peptide need improve the physicochemical properties of the product. Unoptimized peptides 
are sometimes not very water soluble and easily aggregate. Chemical design strategies may 
provide the solution of this problem by modifying of the amino acid structure, introducing 
amino acids to stabilize secondary structures, salt bridge formation, etc. Some software may 
help predict the property of peptide which becomes a good tool to facilitate the design. 
Natural peptides often have a very short plasma half-life. Several techniques for half-life 
extension have been developed. For instance, the enzymatic degradation of peptide can be 
slowed by identification of possible molecular cleavage sites followed by substitution of the 
 10 
 
relevant amino acid; to protect against enzymatic cleavage by enhancing the secondary 
structure of peptide. Peptides can bind to the circulating protein albumin to extend the 
half-life46, 47. Conjugation of polyethylene glycol or (PEG)-ylation can limit renal filtration to 
increase plasma half-life by limiting the elimination of peptides.  
 
Figure 1.9 The traditional structure-based design strategies that are used in peptide drug 
discovery 
There are many natural peptides that have excellent potentency for therapeutics. 
Chemical strategies for the design of multifunctional peptides can include a hybrid of two 
peptides binding together directly or via a linker48.  
Natural peptides normally aren’t able to cross cell membranes, which limited their 
therapeutic use to extracellular targets. But in recent years, scientists have invented some 
peptides which contain membrane permeability elements, which are called “cell penetrating 
peptides”, making it possible to reach intracellular targets with peptides to some degree. One 
challenge of cell penetrating peptides, which is likely to be also shared by orally bioavailable 
peptides, is a potential loss of efficacy because only a fraction of the peptide drug can reach 
the target49.  
 11 
 
It is also important to point out the conjugation of peptides with, for example, small 
molecules, oligoribonucleotides, or antibodies can give novel peptide therapeutics with 
improved efficacy and safety properties50, 51. For example, in peptide-radioactive ligand 
conjugates, the peptide component can ensure targeted delivery of the radioactive ligand to 
the relevant site, with high concentrations of radiotherapeutic agent at the site.  
In summary, peptides have attracted a lot of attention as therapeutics in recent years. 
Patients have benefit from more than 60 peptide based drugs in the market and at the same 
time hundreds of novel therapeutic peptides are in preclinical and clinical trials. The success 
of peptide drug is derived from peptide’s potent and specific, yet safe, mode of action. We 
also expect the application of novel peptide technologies, including multifunctional peptides, 
cell penetrating peptides and peptide drug conjugates, will help expand the applicability of 
peptides as therapeutics.  
1.4 Peptide synthesis 
The synthesis of peptides has become very popular in organic and medicinal chemistry 
labs. Unlike regular organic synthesis, chemists prefer to use solid phase synthesis in peptide 
preparation. Solid phase peptide synthesis (SPPS) was first introduced by Robert Bruce 
Merrifield52. Merrifield won the Nobel prizein Chemistry in 1984 for this invention of SPPS.  
Merrifield’s single author paper published in 1964 on the synthesis of a tetrapeptide is the 
fifth cited paper in the history of the Journal of the American Chemical Society. SPPS allows 
the synthesis of unnatural peptides that incorporate unnatural amino acids and modify the 
peptide backbone53.  
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most important property because it is necessary for diffusion and accessibility of active sites. 
Higher swelling normally means high loading ability. The size of beads is normally about 
80-200 μm. The mesh size is the number of openings in a square inch, normally 70-170.  
There are four major types of resin (Figure 1.11), Cross-linked-polystyrene-resins, 
Polyamine-resins, Tentagel-resins and soluble resins54.  
Ph
PhPh
PhPh
Cross-linked polystyrene Resin
Cl
H
N
O
N
H
O
NHBoc
Backbone monomer of Sheppard 
Resin
CH2
HC OCH2CH2 X
TentaGel Resin
H3C (OCH2CH2)11OH
MEO-PEG(11)-OH
Figure 1.11 Four types of commonly used resins 
Cross-linked-polystyrene-resins are the most commonly used because of their high 
availability, low cost and chemical stability. They can swell in the solvents of low to medium 
polarity like DCM, DMF and toluene, but not in polar and protic solvents like alcohol and 
water. There are some disadvantages of this kind resin used in peptide synthesis. They are not 
rigid enough which may cause the interactions between the active centers. The resin is 
hydrophobic and the peptides are hydrophilic, which means there will be some interactions 
between peptide-peptide chains. The solvents for these kind resins are not very good for fully 
deprotected peptides. 
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 The Sheppard resin is the most common polyamine-resin. It mimics more closely the 
properties of peptide chains. It is better swelling in polar, aprotic solvents like DMF, NMP.  
Tentagel-resin is the polyethylene glycol (PEG) (up to 70%) attached to cross-linked 
polystyrene through an ether link. This kind resin can swell in both protic and aprotic 
solvents. The attached reaction sites project into the solution rather than being anchored close 
to the polymer backbone, which make the reaction condition similar to the solution phase 
chemistry. But Tentagel-resin also has some disadvantages. It has a relatively low loading 
compared to PS-resins. The PEG chains may complex Lewis acid. The PEG chains are not 
very stable under certain condition. 
Meo-PEG resin is soluble in most of solvent, so the reaction on this resin is in 
homogeneous condition and catalysts can be used. After reaction, the resin is easily 
crystallized in diethyl ether and can be further handled like regular resin. 
In peptide synthesis, the most important step is the coupling step which forms the 
peptide bond and connects two amino acids to extend peptide chain. In this step, the coupling 
reagent is used to activate the carboxyl group, and then the amine will attack the activated 
carboxyl as a nucleophile to form the amide bond. The general mechanism is shown in 
Figure 1.12. There are four kinds of coupling reagents which are used for activation of 
carboxyl. They are carbodiimides, symmetrical anhydrides, activated esters and uronium 
based coupling reagents.  
Carbodiimides are very widely used in peptide synthesis, like DCC, DIC, EDC55, 56, 57. 
When these reagents activate carboxyl group, the reaction will produce some insoluble ureas 
in some organic solvents. This can cause inconsistent results in solid phase synthesis. 
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Symmetrical anhydrides are prepared by two molecules of amino acid and one carbodiimide. 
The insoluble urea can be filtered off, and then the synthesized anhydride can be used for 
peptide coupling.  
R1 OH
O
H2N R2+
R1 NH
O
R2
Activation of 
carboxyloc acid
R1 Lg
O
H2N R2
 
Figure 1.12 Mechanism of peptide coupling 
Carbodiimides are so reactive that sometimes cause some problems like racemization of 
the amino acid. Therefore, to solve this problem, triazoles are used. The most important ones 
are 1-hydroxyl-benzotriazole (HOBt)58 and 1-hydroxyl-7-aza-benzotriazole (HOAt)59. These 
reagents can form activated esters which are less reactive to avoid potential racemization.  
Activated esters are the esters with a good leaving group which make them easy to be 
attacked by nucleophiles like amines. The derivatives from pentafluorophenyl (HOPfp) and 
HODhbt are most commonly used in peptide synthesis60. 
 The coupling reagents based on phosphonium were first discussed in 1969 by Gawne et 
al61. BOP was a very popular coupling reagent in many peptide syntheses. But it produces 
hexamethylphosphorotriamide (HMPA), which is a potential human carcinogenic. PyBOP is 
a good replacement of BOP and produces less noxious by product62. Uronium/aminium salts 
bearing a positive carbon in the place of the phosphonium residue have also been reported63. 
These kinds activation reagent have a high efficiency and can reduce the racemization or side 
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product formation.  
Figure 1.13 shows some of the most used activation agents. There are some other 
coupling reagents like amino acid halides and azides which have been used in peptide 
preparation64. They activate the carboxylic acid by generating acid chlorides or fluorides with 
the addition of reagents like cyanuric chloride or fluoride65.  
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Figure 1.13 Coupling reagents commonly used in peptide synthesis 
1.5 Structural Analysis and Purification of Peptides and Protein 
The importance of peptide or protein structure analysis can never be ignored. There are 
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Circular Dichroism (CD) is another technique to determine the structure conformations 
of peptides and proteins. This technology was discovered by Jean-Baptiste Biot, Augustin 
Fresnel, and Aimé Cotton in the first half of the 19th century73. It measures the difference of 
the absorption of right- and left-circularly polarized light by a substance. CD spectroscopy 
has a wide application in many different fields. UV-CD is used in secondary structure 
determination of proteins. UV/Vis-CD is used in charge-transfer transitions investigation74. 
Vibrational CD is used for structure studies of small molecules75.  
In protein, the absorption of interest includes the peptide bonds (below 240 nm), 
aromatic amino acid side chains (range 260-320 nm) and disulfide bonds (weak broad band 
around 260 nm). Absorption below 240 nm is mainly from peptide bonds. So we can get the 
information of the peptide or protein’s secondary structure composition from this region. The 
different types of regular secondary structure of protein give some characteristic CD signal as 
shown in Figure 1.16. 
Matrix Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) is a mass 
analysis technique which offers a quick and easy method of mass analysis using a minimal 
amount of sample76, 77. The principles involved in the MALDI mass analysis can be seen in 
Figure 1.17. 
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alpha-helix
anti-parallel beta-sheet
type I beta-turn
irregular structure
extended 31-helix or poly (Pro) II
helix
  
Figure 1.16 Far UV CD spectra associated with various types of secondary structure.  
 
Figure 1.17 Principles of MALDI 
The sample to be characterized is dispersed in a large excess of matrix material which 
will strongly absorb the incident light. The chromophore in the matrix will make it absorb 
most of the laser radiation and the matrix and the sample will desorb from the surface and the 
peptide will be ionized without fragmentation.  
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MALDI has a lot of applications in chemistry and biochemistry fields. It can 
characterize protein and be used in quality control of peptide synthesis78, 79. It also can be 
used for the N-terminal and C-terminal peptide sequencing80. MALDI-TOF mass 
spectrometers are very commonly used in analysis of biomolecules because their ease of use, 
even non-specialist lab personnel can easily access this technology for very fast and sensitive 
detection. 
In solid phase peptide synthesis, MALDI-TOF-MS is very useful. Recently 
MALDI-TOF-MS have been used to detect peptide/carbohydrate molecules without cleavage 
from the resin81, 82. Figure 1.18 shows the result of MALDI-TOF-MS detection of 
unprotected peptide/carbohydrate from a resin bead. In Figure 1.18 (b) MALDI detection 
yielded a characteristic M+H+ signal at m/z 1247 which is consistent with the expected mass 
of the free peptide (MW = 1245.5 Da). Figure 1.18 (C) is MALDI in carbohydrate solid 
phase synthesis. 
In solid phase peptide synthesis, the crude peptide normally will need further 
purification after cleavage from the resin. Reverse phase HPLC is not only used in analysis, 
but most of time it is used for purification as well. It is such a powerful tool which can almost 
separate peptides/proteins with nearly identical structures. For example, Porcine and human 
insulin differ by just one amino acid and bovine and human insulin differ by only three amino 
acids, reverse phase HPLC can separate them very clearly as shown in Figure 1.1983.  
HPLC is a technique used in analytic chemistry to identify, separate, and quantify the 
components in a mixture. It contains a sampler, column, pumps, and detector. The sampler 
brings the sample mixture into the column by a mobile phase stream. The pumps deliver the 
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1. Choosing the right silica stationary phase based on structure and purity 
Different silicas have different structure, porosity, surface area, mechanical strength, 
pH resistance, purity and pore size distribution. 
2. Pore size selection  
The molecules will enter the pores in the column. The size of pores can affect the 
separation result, the peak width, and the max amount of sample loading. The range 
of pore size is from 80 Ᾰ-300 Ᾰ. If the molecule weight is less the 4000, columns 
with small pore size are used to maximize the loading capacity and retention. If the 
molecule weight is higher than 4000, columns of larger pore size are used to 
maintain high efficiency. To increase loading capacity the column diameter can be 
increased. 
3. Consensus mobile phase 
Acetonitrile is the most commonly used organic solvent in HPLC. It has many 
advantages like low UV cutoff (190 nm), it is volatile and good solubilization. TFA 
or formic acid is often added to the solvent. The concentrate is about 0.1%. The acid 
added is low UV absorbant, volatile, and good solubilization. It can improve peak 
shape, reduce mild anionic ion pairing and it is compatible with MS. Low pH also 
suppresses silanol interactions. 
4. Bonded-phase selection 
Some column materials have much better stability at low pH and high temperature. 
And different peptides have different selectivity on different bonded phases. 
5. Optimization of separation 
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The separation result depends on many factors like gradient time, column size, flow 
rate, and organic range. To get best separation, normally we need optimize all these 
conditions. 
6. Alternative separation solutions 
Sometimes when the component is not stable at low pH, volatile buffer solutions 
need be added to keep the pH higher. 
After considering all these conditions, we can develop a suitable method for peptide 
separation by HPLC. After purification by HPLC, the pure peptide is in an aqueous solution. 
To get a dry and clean product, we normally use lyophilizer to freeze dry the product. In a lab, 
the sample solution in water/ACN is treated by dry ice/acetonitrile or liquid nitrogen. The 
solution will be frozen into a solid. The bottle with the sample will be put into a jar which can 
tolerate high vacuum pressure and connected to the lyophilizer machine. The solvent in the 
sample will be taken off via sublimation under a very low pressure and it typically leaves a 
soft porous solid as final product.   
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CHAPTER TWO 
NOVEL CYCLIC PEPTIDOMIMETIC MTI-101 AGAINST MULTIPLE 
MYELOMA 
 
2.1 Introduction of Multiple Myeloma 
Multiple Myeloma is a kind of cancer formed by malignant plasma cells which are 
found in the bone marrow and diagnosed with blood tests, bone examination, urine protein 
electrophoresis and X-rays1. It can cause the accumulation of cancer cell in the bone marrow. 
The healthy blood cells are then crowded out. Many organs can be affected by myeloma. The 
cancer cells will produce abnormal protein which causes many issues like kidney problems, 
low blood counts, bone and calcium problems, and infections. Scientists have found a few 
risk factors which may cause a higher possibility to develop Multiple Myeloma, such as age, 
gender, race and family history2.  
Multiple myeloma is incurable but treatable. Few cases are linked to risk factors that can 
be avoided. There is no known way to prevent multiple myeloma from developing in the 
people. Data shows multiple myeloma develops in 6.1 per 100,000 people per year3. It’s more 
common in men and it is twice as common in African Americans as it is in 
White-Americans4.  
After multiple myeloma is found and staged, the treatment for it may include5, 6, 7: 
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chemotherapy and other drugs, radiation, surgery, stem cell transplant, etc. Normally, 
different treatments will be applied on the patients at different stages. For early stage, patients 
are often watched closely without starting chemo or other treatments for myeloma. They may 
be started on a bisphosphonate if they have bone disease. For active myeloma (stage II), 
patients are always given a drug therapy, and some drug combinations are considered for 
treatments. With conventional treatment, median survival is 3-4years, which may be extended 
to 5-7 years or longer with advanced treatments. Multiple myeloma is the second most 
common hematological malignancy in US. It constitutes 1% of all cancer and 2% of all 
cancer deaths. The five year survival is 45%.  
Dr. Hazlehurst and co-workers have done a lot of research showing that adhesion of 
leukemia and multiple myeloma cells to the extracellular matrix component fibronectin may 
affect cell survival and potentially inhibit drug induced apoptotic cell death8, 9. There are 
three different types of mammalians’ cell death pathways10, 11(Figure 2.1). The majority of 
cancer cells follow the apoptotic pathway to induce cell death. Now the multi-drug resistance 
of tumor cells to standard cytotoxic drugs has been found12, 13, 14, so it is a good opportunity 
to focus on some new drug candidates with an alternative cell death pathway.  
Traditional drugs like melphalan, cyclophosphamide, etoposide and bendamustine are 
used and the combinations of them sometimes are more effective than monotherapy15, 16. All 
of these chemo drugs can kill the cancer cells but also may damage normal cells. Different 
side effects are shown in the patients depending on the drug type, dose and length of time 
they are taken. Common side effects include hair loss, mouth sores, appetite loss, low blood 
counts, nausea, and vomiting. Most side effects go away once the treatment is finished.  
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Figure 2.1 Pathways for cell death in mammalian cells 
2.2 Background of β-hairpin peptides and β turns 
Organic and medicinal chemists have recently started to focus on the development of 
protein-protein interactions inhibitors. In the anti-cancer drug discovery area, it is a very 
important challenge to design and synthesize peptides and proteins, which have secondary 
structures like α-helices and β-sheets. The β-hairpin is one of the most common secondary 
structures in proteins17. 
The β-hairpin is a motif with two antiparallel strands and a β-turn promoting linker 
(Figure 2.2). There are many reports showing that the β-hairpin motif is a very powerful tool 
to understand the formation of β-sheet peptide or protein18. It has a much simpler and smaller 
structure which may provide more advantages in the study of the conformation stability and 
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how the peptides and proteins fold. Many proteins have a β-hairpin motif for biomolecular 
recognition. Natural β-hairpin motifs have proven they are potential candidates of 
antimicrobial and antiviral drugs19, 20, 21. Therefore, it is of great interest to study β-hairpin 
peptides. Now some β-hairpin motifs have been used in the mimicry of cytokine receptors 
and epitopes of antibodies. And they also can be considered as inhibitors for protein-protein 
and protein-nucleic acid interactions. 
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Figure 2.2 β-hairpin peptides and β-turn 
The linkers in β-hairpin peptides are called β-turns22, 23. Now they are known as a very 
common motif in about 25% of folded peptides and proteins. Because a β-turn can reverse 
the direction of peptide, it plays an interesting role in structure stabilization, folding, and 
intermolecular recognition. To design the β-turns and their mimetics is a very efficient way to 
improve the bioactivity and bioavailabilty of the peptides. 
A synthetic all D-amino acid peptide which was named as HYD1 (KIKMVISWKG) was 
reported to potentially induce tumor cell death in MM (multiple myeloma) cells24, 25, which 
could make it a possible anticancer drug candidate. Dr. Hazlehurst and her co-workers have 
 41 
 
studied and identified the core region of HYD1 as the MVISW peptide fragment, which is 
responsible for its biological activity. Our previous research data has provided the necessary 
support information to further pursue HYD1 and its cyclic derivatives. So first we 
synthesized an all D amino acid analog and compared the bioactivities of the cyclic and linear 
analogs. The results showed the cyclic HYD1 peptide was about twice as active as the linear 
(Figure 2.3). We believe the better activity is from the more stable conformation of the cyclic 
peptide. When the cycle forms, the conformation of peptide gets stabilized because the 
available conformation numbers will be restricted. Therefore, the affinity is improved 
between the peptide and its target if the constrained structure is compatible with target 
binding.  
 
Figure 2.3 Comparison of linear HYD1, cyclized D-cHYD1, and cyclized L-HYD1.  IC50 
values of HYD1, D-cHYD1 and L-cHYD1 are 86.5 uM, 42.3 uM and 20.7 uM, respectively. 
2.3 Peptide Design 
Based on the research result of Dr. Hazlehurst and co-workers, we found the valine 
replacement for isoleucine gaveg better activity. We developed a new cyclized peptide with 
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the recognition strand (MVVSW) and non-recognition strand (KLKLK). These cyclic 
peptidomimetics showed a beta sheet like conformation which potentially can improve the 
affinity of the peptide binding to the target by restricting the number of conformations. We 
also did some energy minimization studies to keep the backbone atoms fixed. Some new beta 
turn linkers have been designed and synthesized.  
Table 2.1 Turn promoters in cyclic peptidomimetics 
 Turn 1 Turn 2 Energy 
Minimization 
1 Methylsulfonamido 
aminoethylglycine 
DPro-LPro -2100 Kcal 
2 Methylsulfonamido 
aminoethylglycine 
Methylsulfonamido 
aminoethylglycine 
-2400 Kcal 
3 L-Pro-Aib DPro-LPro -1400 Kcal 
We also did some studies on structure activity relationships of cyclic peptide. We used 
sequential alanine substitution on the recognition strand of peptide analog to identify the 
bioactive residues. The screening result showed tryptophan, valine and methionine are the 
key building blocks for the binding of cyclic peptide to the cells. Replacing alanine for the 
serine significantly increased the bioactivity. We used norleucine to replace methionine 
because of the oxidation of methionine side chain. The results showed norleucine 
introduction boost of bioactivity. Therefore, we predicted that the recognition strand 
(WAVVN) would further improve the activity of the cyclic analogs.    
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Table 2.2 SAR studies of cyclic peptide analogs 
Peptide  R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 IC50 
2.1 
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15.5±7.7 
57.1±22 
4.1±1.9 
19.0±6.9 
6.2±2.7 
31.1±7.6 
2.6±1.3 
2.9±1.3 
5.9 
5.9±3.4 
12.3 
21.9 
25.9 
41.3 
2.8 
9.7 
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After optimizing the recognition strand of cyclic peptide analogs for best bioactivity, we 
further investigated beta turn promoters. The cyclic peptide contained a constrained 
oxygenated turn promoter and a methylsulfonamide aminoethyl glycine promoter. The 
ether-peptidomimetic amino acid (proline or 2-piperidine carboxylic acid derivatives) can be 
a constrained motif which may potentially reduce the degrees of cyclic peptide freedom and 
improve the binding affinity. We used GLIDE software to do all the modeling studies. 
Conformation search and energy minimization suggested that a five-membered ring of 
D-proline derivatives could be the best one which can stabilize and sustain the intermolecular 
H-bonding. 
The third step is to optimize the non-recognition strand. Our group tried one cyclic 
peptide in which we replaced all leucine in the non-recognition strand with N-methyl glycine. 
We believed that N-methylation of the exo amides wouldn’t change the conformation but it 
would stabilize cyclic beta-hairpin structure and prevent possible peptide aggregation. But the 
modified molecule didn’t show any bioactivity at all. So we thought if we introduce too many 
constraints in the molecule, it might cause disruption of internal H-bonding which stabilized 
the cyclic peptide. Based on all these studies, MTI-101, the final structure was designed and 
synthesized (Figure 2.4). 
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Figure 2.4 Structure of MTI-101 
2.4 Synthesis of beta-turn promoters and MTI-101 
Scheme 2.1 shows the synthesis of the methylsulfonamide aminoethyl glycine beta turn 
promoter. First the selective mono-alkylation was carried under the icy condition with excess 
ethyl diamine reacting with tert-butyl bromoacetate to give compound 2.2. After being 
washed with a little of water, the crude compound 2.2 reacted with Fmoc-OSu to get another 
side chain protected. The mixture was washed by diluted HCl solution and kept overnight in 
-40oC freezer. The crystals formed were compound 2.3 as hydrochloride salt form which can 
be stored in the refrigerator for months. After mesylation of compound 2.3, the tert-butyl 
group was taken off from compound 2.4 to obtain compound 2.5 in excellent yield. The 
product is an Fmoc protected amino acid, which is ready for the solid phase peptide 
synthesis. 
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a) TBBA, DCM ,0 oC - rt
d) HCl, 1,4-dioxane
b) DIEA, FmocOSu, DCM, 0 oC-R.T.
c) MsCl, DIEA, DCM, rt
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N COOH
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CH2COOC(CH3)3
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2.3
2.42.5
Scheme 2.1 Synthesis of Fmoc protected methylsulfonamide aminoethyl glycine beta turn 
promoter 
Scheme 2.2 shows the synthesis of the prolinol derivative beta turn promoter. It started 
from commercial compound Boc-D-Prolinol. First Boc-D-Prolinol was O-alkylated by 
tert-butyl bromoacetate to afford compound 2.7. Then the Boc group in compound 2.7 was 
selectively removed by diluted TFA under low temperature to get compound 2.8. Without 
purification, compound 2.8 was protected by Fmoc-OSu to afford compound 2.9. Then the 
tert-butyl group was removed by TFA to obtain compound 2.10. 
a b
c
d
d) HCl, 1,4-dioxane
a) DIEA, BrCH2CO2tBu, TBAI, DCM, 0 oC   b) TFA, DCM, 0oC
c) FmocCl, DIEA, DCM, rt
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Scheme 2.2 Synthesis of Fmoc protected prolinol-based promoter 
After the promoters were ready, we synthesized the cyclic peptides, MTI-101, by solid 
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phase method as shown in scheme 2.3.  
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 Scheme 2.3 Solid phase synthesis of MTI-101 
The MTI-101 analogs were synthesized using the following general procedure: 
p-nitrophenyl Wang resin (0.69mmol/g, 20 g) was swollen in dichloromethane for 30 minutes. 
Nα-Fmoc-Lys-O-Allyl. TFA (4 equiv.) solution in DCM containing DIEA (8 equiv.) was 
added to the resin in a peptide reaction vessel for 3 hours. The process was repeated twice to 
ensure maximum loading of the Fmoc amino acid on the resin. Nα-Fmoc-Lys-O-Allyl. TFA 
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salt was prepared by deprotection of Nα-Fmoc-Lys(Boc)-O-Allyl using 95% TFA in DCM at 
00C. Fmoc quantification of resin indicated a loading of 0.65 mmol/g of resin.  
The linear protected peptide was then synthesized using standard Fmoc solid phase 
strategy. For each coupling step, 2 equivalents of symmetrical anhydride of Fmoc-amino acid 
(concentration of 220 mM) in DCM were added to the reactor. Each coupling reaction was 
carried out for one hour followed by NMP (3x200 mL) and DCM (4x200 mL) washes. Fmoc 
deprotection was done using 20% piperidine/2% DBU in NMP for (100 mL x 10 mins). Then 
the amino acids used for peptide synthesis were coupled in the following order: 
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Linker T3, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, 
Fmoc-Val-OH, Fmoc-Val-OH, Fmoc-Nle-OH, Linker T1, Fmoc-Lys(Boc)-OH, 
Fmoc-Leu-OH.  
After synthesis of the protected linear peptide, the Fmoc group from last amino acid was 
cleaved by 20% piperidine/2% DBU in DMF. The C-terminal allyl group was then removed 
using 0.2 mol% Pd(PPh3)4 dissolved in CHCl3-AcOH-NMM (37:2:1) (200 mL) for one hour. 
The allyl cleavage procedure was repeated again to ensure complete cleavage. The resulting 
side chain anchored peptide acid resin was then washed with DCM, NMP, MeOH, DCM and 
dried. After allyl deprotection, on resin cyclization of linear peptide was carried out by 
treating peptide side chain anchored peptide acid resin with 4 equivalents of HCTU (220 mM) 
in NMP and 8 equivalents of DIEA for one hour. The peptidyl resin was then washed with 
NMP (3x200 mL) and DCM (4x200 mL).  
After on resin cyclization, the peptide was deprotected from the resin using cleavage 
cocktail of TFA/Phenol/H2O/EDT/TIS (82.5:5:5:5:2.5) solution (150 mL) at room 
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temperature for 30 minutes. The reaction mixture was concentrated and the thick viscous 
liquid was triturated twice with 10 mL of cold diethyl ether. The reaction contents were 
centrifuged to give crude cyclic MTI-101 peptidomimetic. The crude peptidomimetic was 
dissolved in a solution of 0.1% TFA in H2O and freeze-dried to give 35.67 gms of crude 
MTI-101.  
Besides these two beta-turn linkers used in MTI-101, we also synthesized some other 
beta-turn linkers to test. The N-ethylated beta-turn linker 2.11 was prepared to determine if 
the additional constraint may further stabilize the secondary structure of the cyclic peptide. It 
was synthesized from 2-ethyl ethanolamine (Scheme 2.4). Boc protection of the amine was 
the first step, which was followed by O-alkylation of the hydroxyl group. After deprotection 
of the Boc group, Fmoc protection of the amine was introduced. The final product 2.11 was 
obtained by taking off the tert-butyl group.  
a b
c
d
d) 1. FmocOSu, DIEA, DCM  e)HCl/dixane
a) Boc2O, DCM    b) tButyl bromoacetate, NaOH, Toluene, TBAI, 0oC
c) TFA, DCM, 0oC
H
N
OH Boc
N
OH Boc
N
OCH2COOC(CH3)3
H
N
OCH2COOC(CH3)3Fmoc
N
OCH2COOC(CH3)3
e
Fmoc
N
OCH2COOH
2.12 2.13
2.142.152.11
Scheme 2.4 Synthesis of the N-ethylated beta turn promoter 
We also designed a membrane-seeking beta turn linker by introducing a long lipid chain 
into the molecule to determine if it can increase the membrane penetration potential. 
Compound 2.16 and 2.17 were synthesized (Scheme 2.5) from ethylene diamine. The 
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synthesis was started with Boc protection of one side of diamine. Then we introduced two 
different lipid chains into the molecule. One had ten carbons, the other had eighteen. After 
N-alkylation, we changed the protecting group from Boc to Fmoc. Final products 2.16 and 
2.17 were obtained by taking off the tert-butyl group. 
H2N
NH2 H2N
NHBoc
BocHN
NHSO2R
BocHN
N COOC(CH3)3
SO2R
a b
c
d
e
a) (Boc)2O, THF, 0 oC - rt,
d) TFA, DCM, 0 oC
b) DIEA, RSO2Cl, DCM, 0 oC c) BrCH2COOC(CH3)3, NaH, THF, 0 
oC,
H2N
N COOC(CH3)3
SO2R
e)FmocOSu, DIEA, DCM, 0 oC-R.T. , f). TFA, DCM, R.T
FmocHN
N COOC(CH3)3
SO2R
FmocHN
N COOH
SO2R
f
R1 = C10H21
R2 = C18H37
R1 = C10H21
R2 = C18H37
R1 = C10H21
R2 = C18H37
R1 = C10H21
R2 = C18H37
R1 = C10H21
R2 = C18H37
2.18 2.19, 2.20
2.21, 2.222.23, 2.24
2.25, 2.26 2.16, 2.17
 Scheme 2.5 Synthesis of membrane-seeking beta turn linkers 
Another idea was considered to introduce an azide group on the side chain of the linker. 
Azide can be easily reduced into amine. Then we can link other biomolecules to our peptide 
via this amine group to make complex conjugated analogs. Compound 2.27 was synthesized 
from 1,3-propane sultone and ethylene diamine in Scheme 2.6. The ring of 1,3-propane 
sultone was opened by N3 nucleophilic attack. Then it was converted into sulfonyl chloride 
by thionyl chloride treatment (reflux 48 hours). This very active intermediate reacted with 
mono Boc-protected diamine, which was followed by N-alkylation with tert-butyl 
brmomacetate. After changing the protecting group from Boc to Fmoc, final products 2.27 
were achieved by taking off the tert-butyl group. 
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b. SOCl2, reflux, 2 days
b
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2.27
2.28 2.29
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Scheme 2.6 Synthesis of azide side chain beta turn linkers 
After we tried the modification of all these ethylene diamine based linkers, more 
prolinol derivatives were considered to be prepared as the potential linkers. For example, we 
tried compound 2.34 (Scheme 2.7) which contained a thio-ether instead of the original ether 
linkage, and compound 2.35 (Scheme 2.8) in which we introduced the amine instead of the 
hydroxyl group and did further modification.  
a b
c
d
d) 1. TFA, DCM, 0oC, 2. FmocOSu, DIEA, DCM
a) TsCl, DIEA, DCM    b) Methyl thioglycolate, NaH, THF, 0oC
c) NaOH, MeOH
N
OH
Boc
N
OTs
Boc
N
SCH2COOCH3
Boc
N
SCH2COOH
Boc
N
S
Fmoc
O
OH
2.34 2.37
2.362.35
 
Scheme 2.7 Synthesis of prolinol thio-ether promoter 
The synthesis of 2.34 started from Boc D-prolinol. We did the tosylation on the hydroxyl 
group. Then SN2 subsitution reaction by methyl thioglycolate was run. After hydrolysis of 
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the methyl ester, the protecting group was changed to Fmoc and the final product 2.34 was 
obtained.  
a b
d
d) TBBA,DIEA, DCM
a) TsCl, DIEA, DCM    b) NaN3, DMF, 80oC c) H2, Pd/C
N
OH
Boc
N
OTs
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N
N3
Boc
N
NH2
Boc
N
H
N
Boc
O
OC(CH3)3
c
e
N
Ms
N
Boc
O
OC(CH3)3
N
Ms
N
Fmoc
O
OH
e) MsCL, DIEA,DCM
f)HCl/Dixoxane g) FmocOSu, DIEA, 0oC
f g
2.43
2.412.42
2.38 2.39 2.40
 
Scheme 2.8 Synthesis of prolinol amine derivative promoter 
The synthesis of 2.43 started from Boc D-prolinol and tosylation on the hydroxyl group 
too. Then the nucleophilic attack group we used was azide group. The azide group was 
reduced by hydrogenation into free amine. The NH2 was alkylated by tert-butyl bromoacetate 
and mesylated. After replacing Boc by Fmoc, final product 2,35 was obtained. 
2.5 Conclusion 
We successfully synthesized some analogs of cyclic peptides which were designed for 
anti multiple myeloma drug candidates. SPPS technoledge was applied in synthesis. Some of 
them showed very interesting activities. Structure analysis has been studied to prove the 
secondary structure of this kind cyclic peptide.  
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CHAPTER THREE 
PEPTIDE AND PEPTIDOMIMETICS IN 3C HRV PROTEASE DRUG 
DISCOVERY 
3.1 Introduction of Human Rhinovirus (HRV) 
Human Rhinovirus (Figure 3.1), first discovered in 1950s, belongs to a diverse family 
of plus-strand RNA viruses1. There are currently three human rhinovirus (HRV species: A, B 
and C) and more than 100 serotypes, which together with the closely related enterovirus 
species, form the genus enterovirus.  
 
Figure 3.1 HRV genomic structure. 
These viruses are responsible for human diseases ranging from mild respiratory tract 
infections (the common cold) to paralytic poliomyelitis2. So far as we know, there are more 
than 200 different viruses to cause symptoms of the common cold. HRV is estimated to cause 
30%-50% of all cases which make it the most common viral infective agent in human and the 
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main cause of common cold. HRV infection proliferates in temperature between (91-95oF), 
and this is why it occurs primarily in the nose3. There are two modes of transmission of HRV, 
one is by aerosols of respiratory droplet and another is from contaminated surfaces, including 
direct person-person contact4. 
HRV is a 7.2-kb single-stranded, positive-sense RNA virus with a single open reading 
frame joined to a 5′ untranslated region and a short viral priming protein (VPg). The P1 
protein is processed to form the HRV capsid, and P2 and P3 are processed to produce VPg, 
protease, and RNA-dependent RNA polymerase (RDRP)5.  
HRV infection not only causes the common cold, it also leads to some more serious 
conditions, including acute otitis media, sinusitis and lower respiratory tract diseases such as 
pneumonia, bronchitis and bronchiolitis and exacerbation of chronic respiratory illnesses6. 
People with chronic lung diseases7, such as asthma and chronic obstructive pulmonary 
disease (“COPD”)8, are especially vulnerable to HRV infections, which may cause acute 
exacerbations of asthma, emphysema or chronic bronchitis in these more susceptible 
individuals and require hospitalization9. Epidemiological studies have also demonstrated that 
a significant number of pulmonary exacerbations of cystic fibrosis (“CF”) are preceded by 
HRV infections10. HRV is believed to be a primary cause of asthma exacerbations. There is 
currently no effective treatment for infections caused by HRV. Vaccines are unsuccessful. 
After HRVs were first discovered in 1950s, 60 years later, “cure” for the common cold virus 
is ongoing. 
HRVs were classified into two species at the beginning, HRV-A and HRV-B, based on 
phylogenetic sequence criteria11, 12. In the 1960s to 1970s, clinical specimens separated 
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almost 100 different HRV strains, which are known as reference or phototype set. HRV-A has 
74 serotypes and HRV-B has 25 serotypes13, 14. In 2009, the sequencing of the full genomes of 
these 99 serotypes was fully completed. And in 2009, a novel HRV species, HRV-C, was 
identified by some highly sensitive molecular techniques. To date, more than 50 HRV-C 
serotypes have been identified15, 16. 
3.2 Introduction of HRV 3C Protease 
A protease is an enzyme which can performs proteolysis. Proteases are classified into six 
broad groups: serine proteases, threonine proteases, cysteine proteases, aspartate proteases, 
glutamic acid proteases and metalloproteases17, 18.   Now there are almost 400 known 
human proteases, and about 14% of them are the drug targets. The whole complete human 
protease families have been analyzed. There are quite a few advantages and reasons for 
choosing human proteases as potential drug targets19, like their available high-throughput 
assays, small molecule inhibitors, enzymology, biochemistry and so on. Although proteases 
were considered primarily to be protein-degrading enzyme (Figure 3.2), now there are 
growing evidences showing they are very important signaling molecules which maybe 
involved in many vital processes. Some research shows disregulating protease activities may 
directly lead to some diseases like inflammatory, cancer, neurological disorders and 
caidiovascular. There are already a few drugs targeting protease in the market and many more 
are still in research and development.  
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Figure 3.2 Proteases cleaves the protein and how the inhibitors work. 
Human rhinovirus 3C protease (HRV 3C protease) is a cysteine protease which can 
recognize the cleavage site of protein, normally between Glu and Gly (Figure 3.3). The 
mechanism has been shown in Figure 3.4. Rhinoviruses are the most common cause of 
common cold. They are very contagious during the winter time every year. They can live 
more than 3 hours outside human contact. There are almost no vaccines against these kinds of 
viruses. Research shows there is little cross-protection between serotypes. There are some 
new antiviral drugs against HRV infections. Interferon-alpha has been shown to be effective 
against HRV, but patients experienced some side effects like nasal bleeding. And some drug 
resistance has been found in those volunteers. This research has now been abandoned.  
 
Figure 3.3 CLEAVAGE SITE- AKA PreScission Site- Cleaves Gln and Gly, Human 
rhinovirus 3C protease (HRV 3C Protease) is a cysteine protease that recognizes the cleavage 
site of Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro, commonly referred to as the PreScission Site 
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Figure 3.4 Mechanism of how 3C protease cleaves the petide bond 
3.3 Introduction of Coronaviruses 
Coronaviruses are considered another common cause of common cold20 (Figure 3.5). 
But it is hard to assess how significant coronaviruses are the causative agents, because unlike 
HRV, human coronaviruses are hard to grown in the laboratory. These kinds of viruses were 
first described in the 1960s. Then they were subsequently named human coronavirus 229E 
and human coronavirus OC43. In 2003, after the outbreak of SARS (Severe acute respiratory 
syndrome) in Asia21, WHO released a statement which identified a novel coronavirus was the 
causative agent of SARS. Then this virus is named SARS-CoV21, which is the third human 
coronavirus. After SARS, the interest in coronavirus has intensified. The fourth (NL63) and 
fifth (HKU1) human coronaviruses were recently discovered. The more recently identified 
human coronavirus is the sixth one, MERS-CoV, which was found in 201222.  
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Figure 3.5 A general coronavirus morphology representative of all coronaviruses 
Severe acute respiratory syndrome (SARS), a viral respiratory illness which first 
appeared in Southern China in November 2002, was recognized as a global threat in March 
2003 (Figure 3.6). This illness sometime begins with a high fever (above 100.4oF) and is 
associated with chills or other symptoms like headache, body discomfort. After 2-7 days, the 
patients may develop a dry cough which may progress to a condition with low oxygen level 
in the blood. In 10-20% cases, patients need mechanical ventilation. Most patients develop 
pneumonia23.  
The incubation period of SARS is typically 2-7 days. Although CDC recommends 
SARS patients to receive the same treatment which is used in serious community-acquired 
atypical pneumonia, there is no effective treatment. During 12/2002 to 07/2003 WHO 
reported, more than 8000 people worldwide became sick with SARS. 774 patients died and 
there’s no new case reported since late July 2003. As the infectious agent of SARS, 
SARS-CoV is able to be detected by several lab tests, like reverse transcription polymerase 
chain reaction (RT-PCR) test, serologic test and viral culture24. 
 63 
 
 
Figure 3.6 SARS 2003 infections report 
3.4 Drug development situation against HRV and CoV 
Due to the numbers of HRV serotypes, the prophylactic vaccines against HRV are 
considered impractical. So some extensive efforts have been applied in searching for effective 
treatment for HRV infections. And there is no promising treatment on antiviral approach by 
using antibodies or a soluble form of the intracellular adhesion molecule (ICAM-1), the 
receptor for the major group of HRVs, to inhibit the viral attachment to the host cell surface 
and subsequent uncoating during cell entry. In addition, there are some approaches on design 
of antiviral molecules such as isoxazole derivatives, flavinoids, and pyridazines that interact 
with the viral capsid proteins. But none of them received positive clinical results. In recent 
years, development of selective and specific molecules targeting viral protein and enzymes 
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has become the focus. In this regard, the 3C protease encoded by HRVs has become a good 
target25, 26. 
HRV 3C protease is considered as a good target for the development of antiviral agents 
for the reasons shown below. 
It is present in all members of the picornavirus family and the HRV 3C proteases from 
different serotypes share high degree of homology at amino acid level.  
The 3C protease enzyme activity is essential to viral replication as it is required for 
generating functional viral proteins and enzymes. Inhibitors of this enzyme should be 
expected to have broadspectrum activity, block the viral replication process, and prevent new 
virion formation.  
It is also anticipated that HRV 3Cpro inhibitors would have high selectivity since 3Cpro 
is an exceptional cysteine protease differing from other cellular homologue on its unique 
folding and catalytic mechanism. 
In bacterial expression systems, different HRV serotypes have overproduced active 3C 
proteases. The availability of active recombinant HRV 3C protease enzymes gave the 
possibility of biochemical characterization and structure determination of this important viral 
enzyme. Biochemical assays of different formats have been developed for HRV 3C protease 
based on the understanding of the 3C protease substrate specificity. These assays use either 
viral polyprotein fragments or small peptides derived from the 3Cpro native cleavage sites as 
substrates. And all these conducted a quick development of specific inhibitors against HRV 
3C protease.  
1. Peptidyl Aldehyde Based HRV 3C protease Inhibitors27, 28 
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3. Bromomethylketone, Arylketone, α-Ketoamide Based Inhibitors30, 31, 32 
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There is some exciting outcome associated with HRV 3Cpro inhibitor development 
which may benefit in design of inhibitors against the main protease coded by human 
coronavirus that causes severe acute respiratory syndrome (SARS). Structural modeling data 
reveals that the main protease encoded by human coronavirus has a similar protein folding to 
HRV 3Cpro around the active site. Molecular modeling further shows that available HRV 
3Cpro inhibitors may be modified to make them useful for treatment of SARS. A recent 
report from Jain and Vederas introduced a new series of keto-glutamine-bearing molecules 
for treatment of SARS as shown in Figure 3.7. Some insignificant inhibitory potency (IC50 = 
70 μM) was detected35, but interestingly enough, simple replacement of the acyclic P1 with 
the cyclic amide led a much better inhibition activity against the SARS 3C like enzyme 
3CLpro (IC50 = 0.60 μM). 
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Figure 3.7 Molecular Modeling of Tripeptidomimetic inhibitors with SARS-Cov binding 
3.5. Structure analysis and design of 3C protease inhibitors 
In 1999, Agouron Pharmaceuticals, Inc. published an HRV 3CP inhibitor with good 
potent against multiple rhinovirus serotypes. It is an approach of introduce Michael acceptor 
moieties as electron-withdrawing group into 3Cpro peptide substrates. Unlike peptide 
aldehyde derivatives, Michael acceptor can form a very stable covalent bond with cysteine 
protease which we consider it is an irreversible reaction. Compound AG7088 has such a good 
cellular enzymes consistent that make it selected to clinical trial against natural acquired cold 
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in 1998. But after evaluation in Phase II, this compound was failed because of DMPK study 
showing low efficiency. DMPK study showed the ethyl ester group in the warhead part was 
very unstable which made it easy to be degraded in vivo.  
The docking result of AG7088 has been studied and shown. Based on the modeling, the 
inhibitor molecule consists five fragments. The active part (warhead), P1 (in the pocket), P2 
(in the pocket), P3 (free, pointing to the solvent) and P4 (having some space). Since the ethyl 
ester in AG7088 is not stable, we may try some other esters to help the compound be stable, 
for example, lactones. In addition, some reversible warheads like ketoamide are worthy to try.  
Figure 3.8 shows the modeling how this kind molecule binds to the protein. P1 and P2 
are in the pocket, so there is not much room for modification. The size the side chain group is 
limited. But we still can try some similar size but different polarity groups. P3 is complete 
free which is facing the solvent, so it may tolerant many different groups which make it a 
handle to tune the solubility and permeability of the whole molecule. P4 has some space to do 
the modification. 
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Figure 3.8 Molecular modeling of AG7088 (green) 
3.6 Design and synthesis of warheads 
The warhead in AG7088 molecule was a Michael acceptor, double bond with ethyl ester. 
The biological data showed a very attractive activity. But later this compound failed in phase 
II because of lack of efficiency. DMPK study indicated the ester bond connected to the 
double bond was very unstable in vivo which meant the compound was too easy to be 
degraded by biological system.  
In Figure 3.2 we designed some lactone-michael acceptor warheads (irreversible) which 
may be not easy to be recognized by enzyme and can stay longer in the body. At the same 
time, some research showed ketoamide warhead introducing better permeability and good 
activity. Therefore we design and synthesized some ketoamide warheads (reversible) as well. 
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Figure 3.9 Designed irreversible/reversible warheads 
Scheme 3.1 shows the synthesis of lactone warheads. 3-Bromo-5H-furan-2-one was 
reacted with triphenyphosphine to afford compound 3.2, a Wittig reagent, which was reacted 
to aldehyde to form double bond (Michael acceptor) with lactone. For 6-member lactone one, 
we put TMS first, then Br was introduced followed by preparing Wittig reagent 3.6. The 
dimethyl lactone Wittig reagent 3.8 was directly made by dimethyl lactone reacting with 
chlorodiethoxyphosphine. 
After these three Michael acceptor warheads were synthesized, we prepared some 
analogs based on them to do head to head comparsion (Scheme 3.2). The screening results 
showed the five member lactone warhead was the best one. 
The ketoamide warhead was synthesized in the very last step (Scheme 3.3). Once all the 
fragments were assembled, the hydroxyl group next to the amide bond was oxidized by 
Dess-Martin reagent to afford ketoamide structure. 
Once the warheads were synthesized, we incorporated it with P1. Then we did peptide 
coupling to introduce P2, P3 and P4 (Scheme 3.4). 
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Scheme 3.4 General procedure of synthesizing Michael acceptor warhead and the whole 
molecule 
3.7 Opimization of P1 
When we looked at the modeling of how the molecule fits in the protein, the position of 
P1 was in a pocket which means there is no much room for P1 group. The space will only 
allow small size groups. The compounds below for P1 scanning were synthesized. We kept 
same warhead (lactone), P2 (4-F-Phe), P3 (Val) and P4 (Cbz) in the sequence and change P1 
group to test. Based on the scan result we tried, five member ring lactam gave the best 
activity. It may allow 6 member ring in P1 position. But once the some substitution groups 
were put on the ring, the whole molecule was deactivated. 
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The synthesis of all these compounds is shown below. Different amino acid derivatives 
were selected and converted into free amine with methyl ester forms. Compound 3.22 was 
synthesized in large scale by coupling Cbz-Valine to 4-F-Phe. Then compound 3.22 was 
coupled to different P1 followed by reduction of methyl ester with lithium borohydride. The 
primary alcohol was oxidized by SO3-pyr, DMSO and DIPEA to afford aldehyde. Without 
separation, the aldehyde was directly reacted with the warhead Wittig reagent to give the 
Michael acceptor double bond.  
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Scheme 3.5 Synthesis procedures of P1 screening analogs 
After all the compounds were synthesized and purified by HPLC, they were test against 
different virus strains including HRV 14, HRV 15, HRV 16, OC 43 and SARS. Both enzyme 
activity and cellular activity are tested. The result showed even six member ring like 
morpholine and piperidine would deactivate the molecule. The lactam gave the best activity 
about 7.9 nM IC50 in enzyme, but the cellular activity dropped a lot, about 100 times less. 
Now what we can do is to keep the lactam in P1 position and change other parts in the 
molecule to make it more permeable to the cell to improve the cellular data. 
3.8 Optimization of P2 
As the docking information showed, P2 was in the pocket too. Six-membered ring was 
tolerated. Some small alkyl groups may also be acceptable. So 4-F-Phe, Phe, Leu, pyridine 
and cylcopentene were scanned. And we considered if we change the backbone skeleton a 
little bit by changing P2 into a five member ring in the backbone, it may improve the stability 
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and rigidity of the molecule. So some proline derivatives were introduced into the molecule 
backbone. All compounds synthesized for screening are shown below.  
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The synthesis of P2 analogs was similar to the synthesis of P1 analogs. We synthesized 
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the P1-Wh fragments first. We compared 4-F-Phe, Phe and Leu. Analogs of Phe and Leu in 
P2 position were synthesized. We found Phe had similar activity as 4-F-Phe and it was good 
for HRV but poor in CoV. Leu in P2 position can bring a boost in CoV activity but lost almost 
a log in HRV activity. Some polar group like pyridine and dimethyl amine can give good 
enzymatic activities but poor cellular activities. We believed the reason was that the side 
chain was easy to be charged which made it hard to penetrate the cell wall. Here is one 
example of the synthesis of one P2 Phe analog in Scheme 3.6.  
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Scheme 3.6 Synthesis of P2-Phe analog 
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 Scheme 3.8 Synthesis of P2 analog with ketoamide warhead 
 
More synthesis of these two libraries will be shown in P3 screen part. The synthesis 
route of different P2 analogs is shown in Scheme 3.7 and 3.8. 
After modeling the change the backbone with proline derivatives, the calculated data 
indicated the ring may stabilize the binding between the molecule and protein. Some analogs 
were synthesized and screened. All of them showed activities against HRV 16, 15 and 14 
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strains. The phenyl group on the ring deactivated the molecule a little, especially for the 
phenyl in (3) position. The double bond on the proline ring also dropped the activity. The one 
containing two methyl groups in (4) position gave a good HRV activity (6.3 nm, enzymatic) 
and didn’t decrease the activity against SARS. Then we tried another five member ring 
3,4-Dihydro-2H-pyrazole, the HRV enzymatic activity was even a little better (5 nm) but lost 
most SARS activity. The synthesis route is shown in Scheme 3.9 below.  
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 Scheme 3.9 Synthesis of P2 skeleton screen 
3.9 Optimization of P3 
As shown in modeling information, P3 is directing to the solvent. So there is enough 
space to tolerate different groups. We synthesized more than 60 analogs for P3 screen. Most 
of them had activities which proved P3 can be the part to do more tuning. 
 First we tried some small alkyl groups like alanine, leucine, valine and others. All of 
them gave the HRV activities range about 100 nm or higher which is about 10 times less than 
the standard one. Then six-membered ring like cyclohexyl amine was tested. The activity 
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increased to about 30 nm. When we put different aromatic rings on P3 position, they showed 
quite different in enzymatic/cellular activities. Both pyridine and benzene ring showed good 
activities. Benzene ring had a better cellular data and pyridine had a better enzymatic data. 
We believed the reason was pyridine was much easier to be protonated which made it easy to 
dissolve in water but hard to penetrate the cell wall.  
P2-Phe and P2-Leu were two major analogs when we did P3-screen. Scheme 3.10 and 
3.11 show the synthesis and all the functional groups we have tried.  
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Scheme 3.10 Synthesis of P3 screen of P2-Phe analogs  
Because P2-Phe analogs gave better result in HRV and P2-Leu analogs gave better result 
in Corona Virus, we screened both when we synthesized different P3 analogs and compared 
them. The best P3-P2-Leu analogs can give 10-30 nm in HRV and 60-80 nm in SARS. The 
P2-Phe analogs can’t provide much SARS activity (125 nm the best), but the best HRV data 
can be 3 nm. 
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Scheme 3.11 Synthesis of P3 screen of P2-Leu analogs 
After single ring groups were tested, we tried some bis-aromatic groups. The first one 
we tested was naphthyl group with P2-Leu. Normally P2-Leu analog would give a better 
SARS result and relatively worse HRV result. But this one had a good HRV activity (about 10 
nm) and moderate SARS activity (63 nm). After further DMPK study, the solubility of this 
compound was not good. So we decided to test more bis-aromatic groups, like quinoline 
derivatives, indanyl group. And at the same time, we tried some side chain which had one 
ring with substituted group on it, which made it had similar size as bis-rings group in docking 
model. All the compounds have been synthesized and screened against HRV 16, 15, 14 and 
OC43, SARS.  
3.10 Optimization of P4 
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Although there was some space for P4 modification, our best candidates were still 
3-methyl isoxazole and Cbz groups. Cbz group showed good SARS activity and moderate 
HRV activity. Isoxazole groups showed excellent HRV activity and poor SARS activity.  
In P4-screen, first we tried to add an extra methylene group between P3 and P4 to see 
how one extra carbon will affect the activity. We also tried to add one or two methyl groups 
on this carbon. The analogs we synthesized are shown in Figure X. After screening, we 
found the single methylene group completely deactivated the whole molecule. But one 
methyl group on this carbon would bring the activity back to normal. Two methyl groups 
didn’t give a better result.  
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The synthesis of P4 analogs was normal. Some different warheads were used to make a 
head to head comparison. Scheme 3.12 shows all the synthesis of P4 screen analogs.  
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 Scheme 3.12 Synthesis of P4 screening analogs 
3.11 The synthesis of unnatural amino acids 
In order to screen more amino acids with different side chains, we had to synthesize 
some of them because they were not commercial available. There are many methods to 
introduce side chain to an amino acid. We chose different methods to synthesize the amino 
acids based on the type of side chains. 
For example, when we want to put six-membered ring cyclic amine on the side chain, 
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we put TMS group on the secondary amine first. The intermediate reacted with 
(2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester to open the 4 member lactone ring. There 
were two possible ways to get the ring open which would result two different products. Only 
one of them was our desired compound. But we can choose the reaction conditions to keep 
the desired one being the major product. And the byproduct was easily separated by HPLC. 
Scheme 3.13 shows the synthesis of this type of amino acids. 
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Scheme 3.13 Synthesis of some unnatural amino acids with cyclohexyl amine side chain 
When we wanted to introduce some aromatic ring on the side chain of amino acid, there 
was a general method to prepare this type amino acid. 6-Oxo-2,3-diphenyl 
-morpholine-4-carboxylic acid benzyl ester was used. Two chiral phenyl groups on the ring 
can direct the stereo chemistry when we did the alkylation on the carbon which was next to 
the carbonyl group. Then the ring was opened and all the protecting groups were removed by 
hydrogenation. In case of double bond in the side chain, which meant hydrogenation can’t be 
applied, we used liquid ammonia with lithium metal to remove the ring.  Scheme 3.14 
shows the synthesis of this type of amino acids. 
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Scheme 3.14 Synthesis of some unnatural amino acids 
There was another method which was only one step reaction to prepare the amino acid 
with aromatic side chain. It was zinc catalyzed Negishi coupling reaction. Iodide alanine can 
react with aromatic bromine with the catalyst Zinc, iodine and Pd. Not all the aromatic 
bromine worked under this condition. Scheme 3.15 shows what we prepared.  
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Scheme 3.15 Synthesis of some amino acids via Negishi coupling reaction 
There were some other amino acids we prepared under different conditions. For example, 
under high pressure H2 with 25% Pd/C, we reduced pyridine ring on the side chain into 
cyclohexyl amine. We used acyl ethyl ester to react with TMS-diazomethane to form a five 
member ring. It gave a mixture of two isomers which were purified after they were coupled 
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with other molecules. Scheme 3.16 shows the synthesis. 
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Scheme 3.16 Synthesis of some unnatural amino acids 
3.12 Conclusion 
After we did a lot of docking models, we can figure out the binding information of the 
inhibitor with the protein. X-ray crystal structure study also has been applied on some 
inhibitor-protein complex. Based on the information, we designed the molecules which may 
give the activities against both HRV and Corona Virus. Different warheads were screened 
including reversible and irreversible types. P1 to P4 groups have been optimized. We also did 
some skeleton modification work to check the activities. Totally we have synthesized more 
than 100 final molecules for screening. They were tested against HRV 16, 15, 14 three 
different HRV strains, and SARS, OC43 two Corona Virus strains. For HRV test, we did both 
enzymatic and cellular test. Most of them showed activities as we expected.  
After we compared the biological data of all these molecules, we can make some 
conclusion here. For warhead, lactone warhead can improve the solubility and lung stability, 
but reduce the permeability into the cell. Ketoamide warhead has a better permeability, but 
lower activity. P1 group can only tolerate lactam, all other groups lose the activities. P2 group 
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can have some choices. 4-F-Phe and Phe are similar which are both favored by HRV. Leucine 
is much better in CoV but a little activity loss in HRV. P3 group is the one we screened most. 
It is exposed to the solvent. Water soluble groups and greasy groups can both be tolerated. 
Bis-aromatic rings gave a good data in HRV but not well in solubility. We can use this part as 
a handle to do fine tuning between the solubility and permeability. P4 group only has two 
choices after screening. Cbz group in P4 can provide good activity for HRV and CoV but 
poor solubility. Isoxazole group can provide best HRV activity but almost no CoV activity. 
Based on all the data and analysis, it seems we still need do further optimization on this 
kind molecule although we already have a good progress. So, more compounds need be 
synthesized and screened. More details in X-ray crystal structure study may help us find the 
best candidate. 
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CHAPTER FOUR 
EXPERIMENTAL PART 
Synthesis of compound 2.5 
FmocHN
N COOH
SO2CH3
 
 A solution of t-butyl bromoacetate (27.6 mL) in 150 mL DCM was added dropwise to 
a solution of ethylenediamine (100 mL) in 700 mL DCM at 0oC for a period of 30 mins. The 
reaction mixture was allowed to warm to room temperature and stirred for over night. The 
solution was washed by water (150 mL). The aqueous layer was extracted with DCM (100 
mL) twice. The combined organic layers were dried by Na2SO4. The solvent was removed 
and dried in vacuo for next step. Compound 2.2 was obtained as yellow oil 
The crude compound 2.2 (22 mL) was dissolved in DCM (1000 mL) with DIEA (22 
mL). A solution of   FmocOSu (41 g) in 300 mL was added in 1 hour. The reaction was 
stirred for over night and washed by 1M HCl (100 mL) twice. The organic layer was dried by 
Na2SO4 and concentrated to 70 mL. After cooled in freezer for two days, a white solid was 
formed and filtered. The solid 2.3 was dried by vaccum.  
T-butyl-N-[2-(N-9-fluorenylmethoxycarbonyl)aminoethyl]-N-methylsulfonamido 
glycinate. (5 g) was dissolved in 50 mL THF with 4 mL DIEA. MsCl (0.9 mL) was added 
into the reaction at 0oC. The reaction mixture was stirred for 3 hours. After removal of the 
solvent, the residue was partitioned between DCM and water. The organic layer was partially 
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concentrated and cooled in freezer. A white solid 2.4 was formed and filtered 
Compound 2.4 (5 g) was dissolved in 1,4-dioxane and 4M HCl was added. After the 
reaction is complete, reaction contents were filtered to give compound 2.5 as a white solid.  
Synthesis of compound 2.10 
N
O
Fmoc
O
OH
 
Boc-D-prolinol 2.6 (3 g) was dissolved in 50 mL toluene. 30 mL NaOH (30%) was 
added at 0oC.  TBBA (4.35 mL, 2 eq) and TBAI (2.0 g, 0.5 eq) were added. The reaction 
mixture was stirred for over night. After the reaction was complete, another 50 mL toluene 
was added. The organic layer was washed by 1 M HCl (50 mL, twice), saturated NaHCO3 (50 
mL, twice), brine (50 mL). After dried by anhydrous sodium sulfate, the residue was purified 
by column. A yellow oil 2.7 was obtained.  
Compound 2.7 (1.8 g) was dissolved in 20 mL DCM. TFA (5 mL) was added at 0oC. 
The reaction mixture was stirred for 30 mins. Then the solvent and TFA were removed by 
vacuum. The crude product 2.8 was directly used for next step without further purification.  
Compound 36 (1.6 g) was dissolved in 30 mL DCM with DIEA (0.9 mL, 2eq). 
FmocOSu (1.69 g, 1eq) was added at 0oC. After 3 hours, the reaction was complete. The 
solvent was removed by rotavap. The residue was dissolved in EA (50 mL) and washed by 1 
M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After dried by 
anhydrous sodium sulfate, the residue was purified by column. A white solid 2.9 was 
obtained.  
Compound 2.9 (0.98 g) was dissolved in 15 mL dioxane. 10 mL HCl (10 M) was added 
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into the reaction. After 1.4 hours, the reaction was complete. The solvent was removed by 
vacuum. A white solid 2.10 was obtained. 
 Synthesis of compound 2.11 
Fmoc
N
OCH2COOH 
Boc anhydride (5.18 g) was dissolved in 20 mL dry DCM. The solution of  
2-Ethylamino-ethanol (2 g) in 10 mL DCM was added at 0oC. After 3 hours, the reaction was 
complete. The solvent was removed by rotavap. The residue was dissolved in EA (30 mL) 
and washed by 1 M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). 
After dried by anhydrous sodium sulfate, the solution 2.12 was concentrated for next step 
directly.  
Compound 2.12 was dissolved in toluene (20 mL). NaOH solution (30%, 24 mL) was 
added at 0oC. TBBA (4.1 mL, 2 eq) and TBAI (1.9 g, 0.5 eq) were added. The reaction 
mixture was stirred for over night. After it was complete, another 20 mL toluene was added. 
The organic layer was washed by 1 M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), 
brine (50 mL). After dried by anhydrous sodium sulfate, the residue was purified by column. 
A yellow oil 2.13 was obtained.  
Compound 2.13 (1 g) was dissolved in 20 mL DCM. TFA (5 mL) was added at 0oC. The 
reaction mixture was stirred for 30 mins. Then the solvent and TFA were removed by vacuum. 
The crude product 2.14 was directly used for next step without further purification.  
Compound 2.14 (0.5 g) was dissolved in 15 mL DCM with DIEA (0.44 mL). FmocOSu 
(0.57 g, 1eq) was added at 0oC. After 3 hours, the reaction was complete. The solvent was 
removed by rotavap. The residue was dissolved in EA (30 mL) and washed by 1 M HCl (50 
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mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After dried by anhydrous 
sodium sulfate, the residue was purified by column. A yellow oil 2.15 was obtained. 
Compound 2.15 (0.98 g) was dissolved in 15 mL dioxane. 10 mL HCl (10 M) was 
added into the reaction. After 1.4 hours, the reaction was complete. The solvent was removed 
by vacuum. A white solid 2.11 was obtained. 
Synthesis of compound 2.16 
FmocHN
N COOH
SO2C10H21
 
Ethylene diamine (40 mL) was dissolved in 200 mL THF (solution A). Boc Anhydride 
(20 g) was dissolved in 150 mL THF (solution B). The reaction was carried under 0oC. 
Solution B was added into solution A in 40 minutes by dropping funnel. The reaction was 
kept for over night. Then the solvent was removed by rotovap. 500 mL ethyl acetate was 
added to the residue. The solution was washed by 50 mL water. The aqueous layer was 
extracted by 50 mL ethyl acetate twice. All The organic layers were combined and dried by 
anhydrous sodium sulfate. After removal of solvent, a yellow oil 2.18 was obtained. 
Compound 2.18 (0.28 g) and DIEA (0.25 mL, 1 eq) was dissolved in 15 mL DCM 
(solution A). Decanesulfonyl chloride (0.4 g, 1 eq) was dissolved in 10 mL DCM (solution B). 
Solution B was added into solution A in half 10 mins under 0oC. The reaction was complete 
in 15 mins. The solution was washed by 1 M HCl (10 mL, twice), saturated NaHCO3 (10 mL, 
twice), brine (10 mL). After dried by anhydrous sodium sulfate, the residue was purified by 
column. A yellow oil 2.19 was obtained.  
Compound 2.19 (0.5 g) was dissolved in THF (20 mL) with t-butyl bromoacetate (0.22 
mL, 1.0 eq). NaH (0.11g 2eq) were added at 0oC. After over night, the reaction was complete. 
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THF was removed by vacuum. The residue was diluted by 50 mL EA. The solution was 
washed by 1 M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After 
dried by anhydrous sodium sulfate, the mixture was purified by column. A yellow oil 2.21 
was obtained. 
Compound 2.21 (1.2 g) was dissolved in DCM (20 mL), 5 mL TFA was added into the 
solution under 0oC. After confirmed by TLC, the reaction was completed in 40 minutes. The 
solvent and TFA was removed by rotovap. Extra DCM (20 mL* 3) was used to get rid of all 
the TFA in solution. The product 2.23 was dried by high pressure vacuum for over night. 
The crude compound 2.23 was dissolved in DCM (50 mL) with DIEA (0.77 mL, 2 eq ). 
FmocOSu (0.8 g, 1 eq)) was added. at 0oC. After 3 hours, the reaction was complete. The 
solvent was removed by rotavap. The residue was dissolved in EA (50 mL) and washed by 1 
M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After dried by 
anhydrous sodium sulfate, the residue was purified by column. A white solid 2.25 was 
obtained. 
Compound 2.25 (0.9 g) was dissolved in MeOH (15 mL). Pd/C (catalyst) was added 
slowly. The reaction was carried in high pressure hydrogenater. After over night, the reaction 
was complete. The solution was filtered by celite. White solid 2.16 was obtained by removal 
of the solvent.  
Synthesis of compound 2.27  
FmocHN
NSO2(CH2)3N3
CH2COOH
 
Solution A was prepared by dissolving 1,3-propane sultone (4.885 g) in 25 mL acetone. 
Solution B was prepared by dissolving sodium azide (1eq, 2.6 g) in 15 mL water and 50 mL 
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acetone. Solution B was added to solution A dropwise in 20 minutes. The reaction was kept 
under room temperature for over night. After it was complete, the solution mixture was dried 
by removal of the solvent. A white solid 2.28 was obtained. 
Compound 2.28 was dissolved in thionyl chloride (50 mL). The reaction was kept under 
reflux condition for two days. Then the mixture was filtered. After removal of the solvent in 
the filtrate, a brown oil 2.29 was obtained. 
Compound 2.18 (0.28 g) and DIEA (0.25 mL, 1 eq) was dissolved in 15 mL DCM 
(solution A). Compound 2.29 (0.4 g, 1 eq), was dissolved in 10 mL DCM (solution B). 
Solution B was added into solution A in half 10 mins under 0oC. The reaction was complete 
in 15 mins. The solution was washed by 1 M HCl (10 mL, twice), saturated NaHCO3 (10 mL, 
twice), brine (10 mL). After dried by anhydrous sodium sulfate, the residue was purified by 
column. A yellow oil 2.30 was obtained.  
Compound 2.30 (0.5 g) was dissolved in THF (20 mL) with t-butyl bromoacetate (0.22 
mL, 1.0 eq). NaH (0.11g 2eq) were added at 0oC. After over night, the reaction was complete. 
THF was removed by vacuum. The residue was diluted by 50 mL EA. The solution was 
washed by 1 M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After 
dried by anhydrous sodium sulfate, the mixture was purified by column. A yellow oil 2.31 
was obtained. 
Compound 2.31 (1.2 g) was dissolved in DCM (20 mL), 5 mL TFA was added into the 
solution under 0oC. After confirmed by TLC, the reaction was completed in 40 minutes. The 
solvent and TFA was removed by rotovap. Extra DCM (20 mL* 3) was used to get rid of all 
the TFA in solution. The product 2.32 was dried by high vacuum for over night. 
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The crude compound 2.32 was dissolved in DCM (50 mL) with DIEA (0.77 mL, 2 eq ). 
FmocOSu (0.8 g, 1 eq)) was added. at 0oC. After 3 hours, the reaction was complete. The 
solvent was removed by rotavap. The residue was dissolved in EA (50 mL) and washed by 1 
M HCl (50 mL, twice), saturated NaHCO3 (50 mL, twice), brine (50 mL). After dried by 
anhydrous sodium sulfate, the residue was purified by column. A white solid 2.33 was 
obtained. 
Compound 2.33 (0.9 g) was dissolved in DCM (15 mL). TFA (10mL) was added slowly. 
The reaction was carried at room temperature. After over night, the reaction was complete. 
The solution was filtered by celite. A colorless oil 2.27 was obtained by removal of the 
solvent.  
Synthesis of compound 2.34 
N
S
Fmoc
O
OH
 
Boc-D-prolinol (0.5 g) was dissolved in 20 mL DCM. TsCl (0.57 g, 1.2eq) was added 
with DIEA (0.6 mL, 1.5 eq). DMAP (0.1 g) was added as a catalyst. The reaction mixture was 
stirred for over night. After the reaction was complete, the organic layer was washed by 1 M 
HCl (10 mL, twice), saturated NaHCO3 (10 mL, twice), brine (10 mL). After dried by 
anhydrous sodium sulfate, the residue was purified by column. A yellow oil 2.35 was 
obtained.  
Compound 2.35 (1.0 g) was dissolved in 20 mL dry THF. Methyl thioglycolate (0.32 
mL, 1.2 eq) was added. The solution was cooled to 0oC. Then sodium hydride (0.47 g, 4 eq) 
was added. The reaction mixture was stirred for over night. Then 1 mL methanol was added 
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to quench the reaction. After the solvent was removed by vacuum, the residue was purified by 
column. A yellow oil 2.36 was obtained. 
Compound 2.36 (0.57 g) was dissolved in 10 mL methanol with sodium hydroxide (1 g). 
After 1 hour, the reaction was complete. After removal of the solvent, 20 mL EA was added 
to the residue. The mixture was washed by 1 M HCl (10 mL, twice), saturated NaHCO3 (10 
mL, twice), brine (10 mL). After dried by anhydrous sodium sulfate, the crude product 2.37 
was directly used to next step. 
Compound 2.37 was dissolved in 20 mL DCM. TFA (5 mL) was added at 0oC. The 
reaction mixture was stirred for 30 mins. Then the solvent and TFA were removed by vacuum. 
The crude product was dissolved in 30 mL DCM with DIEA (0.63 mL, 2eq). FmocOSu (0.7 g, 
1eq) was added at 0oC. After 3 hours, the reaction was complete. The solvent was removed 
by rotavap. The residue was dissolved in EA (50 mL) and washed by 1 M HCl (30 mL, twice), 
brine (30 mL). After dried by anhydrous sodium sulfate, the residue was purified by column. 
A brown oil 2.34 was obtained.  
Synthesis of compound 2.43 
N
Ms
N
Fmoc
O
OH
 
Boc-D-prolinol (0.5 g) was dissolved in 20 mL DCM. TsCl (0.57 g, 1.2eq) was added 
with DIEA (0.6 mL, 1.5 eq). DMAP (0.1 g) was added as a catalyst. The reaction mixture was 
stirred for over night. After the reaction was complete, The organic layer was washed by 1 M 
HCl (10 mL, twice), saturated NaHCO3 (10 mL, twice), brine (10 mL). After dried by 
anhydrous sodium sulfate, the residue was purified by column. A yellow oil 2.38 was 
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obtained.  
Compound 2.38 (1.0 g) was dissolved in 10 mL dry DMF. Sodium azide (1.2 eq) was 
added. The solution was heated to 80oC for over night. Then the solution was cooled to room 
temperature and diluted by 30 mL EA. The mixture was washed by 1 M HCl (10 mL, twice), 
saturated NaHCO3 (10 mL, twice), brine (10 mL). After dried by anhydrous sodium sulfate, 
the residue was purified by column. A yellow oil 2.39 was obtained. 
Compound 2.39 (0.57 g) was dissolved in 10 mL methanol. The solution was slowly 
added Pd/C. After hydrogenation for 6 hour, the reaction was complete. After removal of the 
solvent, the crude product 2.40 was directly used to next step. 
Compound 2.40 was dissolved in 20 mL DCM with DIEA. TBBA was added at 0oC. 
The reaction mixture was stirred for over night. Then the solution was cooled to room 
temperature and diluted by 30 mL EA. The mixture was washed by 1 M HCl (10 mL, twice), 
saturated NaHCO3 (10 mL, twice), brine (10 mL). After dried by anhydrous sodium sulfate, 
the residue was purified by column. A yellow oil 2.41 was obtained. 
Compound 2.41 was dissolved in 10 mL DCM with DIEA. MsCl was added slowly 
under 0oC. After 1 hour, the reaction was complete. Then the solution was cooled to room 
temperature and diluted by 30 mL EA. The mixture was washed by 1 M HCl (10 mL, twice), 
saturated NaHCO3 (10 mL, twice), brine (10 mL). After dried by anhydrous sodium sulfate, 
the residue 2.42 was directly used in next step. 
Compound 2.42 was dissolved in HCl/Dioxane. The reaction was stirred for 1 hour. 
Then the solvent was removed. The residue was dried for over night. Then it was dissolved in 
THF at 0oC with 4 eq DIEA. FmocOSu was added slowly. After 3 hours, the reaction was 
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complete. Then the solution was cooled to room temperature and diluted by 30 mL EA. The 
mixture was washed by 1 M HCl (10 mL, twice), saturated NaHCO3 (10 mL, twice), brine 
(10 mL). After dried by anhydrous sodium sulfate, the residue was purified by column. A 
yellow oil 2.43 was obtained. 
Synthesis of compound 3.2  
O
O
PPh
Ph
Ph
Br  
3-Bromo-dihydro-furan-2-one and triphenylphosphine are dissolved in THF. Then it is 
heated to reflux. After 2 days, the reaction is complete. White solid is precipitated out. After 
removal of THF, the mixture is diluted by 10 mL Et2O. After stirred for 2 hours, solid 3.2 is 
collected by filtration. It is used in next step without further purification. 
Synthesis of compound 3.6 
O
O
P
Ph
Ph
Ph
Br  
Tetrahydro-2H-pyran-2-one is dissolved in THF at -78 °C. LDA solution is added. After 
30 mins, TMSCl is added dropwised. The reaction is kept under -78 °C for another hour and 
then warmed up to room temperature. After removal of THF, the mixture is diluted by hexane 
(10 mL) and flitered. The filtrate is concentrated and purified by vacuum distillation. 
Colorless oil is collected. 
The oil is dissolved in dry DCM at -20°C. Bromine is added dropwised. After 30 mins, 
the mixture is concentrated and purified by Column (silica gel, DCM/MeOH, 0-20%). 
Compound 3.5 is obtained. Yield is 14% for two steps. 
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3-Bromotetrahydro-2H-pyran-2-one and triphenylphosphine are dissolved in THF. Then 
it is heated to reflux. After 2 days, the reaction is complete. White solid is precipitated out. 
After removal of THF, the mixture is diluted by 10 mL Et2O. After stirred for 2 hours, solid 
3.6 is collected by filtration. It is used in next step without further purification. Yield is 44%. 
Synthesis of compound 3.8 
O
O
PO
O
O
 
LDA is dissolved in dry THF at -78 °C. 5,5-dimethyldihydrofuran-2(3H)-one in THF 
solution is added dropwised under N2 protection. After 30 mins, diethyl chlorophosphite is 
added dropwised. The reaction is warmed up to room temperature in 1 hour. After 1.5 hours, 
TLC shows the starting material is gone, new more polar spot forms (2:1, EA:HX). The 
reaction is quenched by acetic acid in ether solution (3 mL). The mixture is filtered by celite. 
The flitrate is concentrated.The residue is open to the air under stirring for over night. Then 
compound 3.8 is purified by column (silica gel, 0-30%, EtOH: DCM). Yield is 94%. 
Synthesis of compound 3.9 
N
H
H
N
F
O
N
H
H
N
O
O
O
O
O
O
 
(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl) 
propanoic acid is dissolved in 4 mL DMF at 0 °C. (S)-3-((S,E)-2-amino-3- 
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(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one and DIEA are added. After 5 
mins, T3P is added dropwised. The reaction is complete after 30 mins. Then 50 mL ethyl 
acetate is added. The solution is washed by NaHCO3 (twice), brine (twice). After dried by 
Na2SO4, 2 mL ethyl acetate is added to the residue. Then 5 mL diethyl ether is added. White 
solid is precipitated out. The product 3.9 is collected by filtration. Yield is 56.4%. 
Synthesis of compound 3.10, 3.11, 3.12 
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(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl) 
propanoic acid is dissolved in DMF at 0 °C. DIEA and methyl 2-amino-3- 
((tertbutoxycarbonyl) amino)propanoate are added. Then T3P is added slowly. After 20 mins, 
the reaction is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and 
brine. The water layer is combined and extracted by 10 mL EA. Combined EA is dried by 
Na2SO4. After removal of the sovlent, the white solid is washed by ether and collected by 
filtration as product 3.26. 
(5S,8S,11S)-Methyl-11-(((tert-butoxycarbonyl)amino)methyl)-8-(4-fluorobenzyl)-5-isop
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ropyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/ 
Methanol at 0 °C. LiBH4 solution is added. The reaction is complete after 30 mins. The 
solution is diluted by 30 mL EA and washed by brine. After removal of the solvent, the white 
solid is the product 3.27. 
Compound 3.27 is dissolved in DCM/DMSO at 0 °C. DIEA and SO3-pyr are added. 
After 40 mins, the reaction is complete. Then 2-oxotetrahydrofuran-3-yl) 
triphenylphosphonium, Bromide is added. The reaction is kept for over night. Then the 
solution is diluted by 50 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4 and concentrated. The residue is washed by DCM/Ether 1:1 solvent. Pale 
yellow solid is filtered and collected as product 3.10. Yield is 78%. 
Compound 3.10 is dissolved in 4 mL HCl/dioxane solution. The reaction is complete 
after 15 mins. The solvent is removed. Crude product 3.29 is directly used for next step. 
Benzyl((S)-1-(((S)-1-(((R,E)-1-amino-3-(2-oxodihydrofuran-3(2H)-ylidene)propan-2-yl)
amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)amino)- 3-methyl-1-oxobutan-2-yl)carbamate, 
Hydrochloride is dissolved in Ac2O/DMF. DIEA is added. After 2 hours, the reaction is 
complete. 30 mL EA is added to dilute the solution. The organic layer is washed by NaHCO3 
and brine. After dried by Na2SO4, the solvent is removed. HPLC is applied to purify the final 
product 3.11 which is a white solid. Yield is 45.9%. 
Benzyl((S)-1-(((S)-1-(((R,E)-1-amino-3-(2-oxodihydrofuran-3(2H)-ylidene)propan-2-yl)
amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate, 
Hydrochloride is dissolved in dry DMF at 0 °C. DIEA is added. Then isoxazole-5-carbonyl 
chloride is added. The reaction is kept at 0 °C for 2 hours. LCMS shows the reaction is over 
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reacted. There's some di-subsitituted product formed. Then 30 mL EA is added the reaction. 
The solution is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. HPLC 
is applied to purify the products 3.12. Yield is 40.1%. 
Synthesis of compound 3.13 
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Boc-serine methyl ester is dissolved in 5 mL HCl (4 N in dioxane) at 0 °C. After 20 mins, 
the reaction is complete. Some white solid forms on bottom. Remove all the solvent. The 
residue is dried by vacuum for 10 mins. Then it is dissolved in 5 mL 
DMF.(S)-2-((S)-2-(((benzyloxy )carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl)pr
opanoic acid and DIEA are added. The reaction is cooled to 0 °C and T3P is added slowly. 
After 30 mins, the reaction is done. The solution is diluted by 30 mL EA and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, pale 
yellow solid 3.32 is collected as crude product for next step. 
(5S,8S,11S)-Methyl-8-(4-fluorobenzyl)-11-(hydroxymethyl)-5-isopropyl-3,6,9-trioxo-1-
phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in 5 mL DMF. MsCl and DIEA are 
added at 0 °C. TLC of step 1: Rf=0.8, EA:HX=2:1, UV. After 45 mins, morpholine is added 
at 0 °C. The reaction is kept at 0 °C for 25 mins and then warm up to room temperature. After 
40 mins, the reaction is complete. Solution is concentrated. Then 40 mL EA is added and 
washed by Na2CO3 and brine. The organic layer is dried by Na2SO4 and concentrated. After 
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column (DCM:20% Methanol in DCM = 0-50%), white solid 3.33 is isolated as product. 
(5S,8S,11S)-Methyl-8-(4-fluorobenzyl)-5-isopropyl-11-(morpholinomethyl)-3,6,9-trioxo
-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/MeOH. The solution is 
cooled to 0 °C. Then LiBH4 solution is added slowly. After 30 mins, the reaction is complete 
which is confirmed by LCMS. 10 mL NaHCO3 solution is added. Then 50 mL EA and 10 mL 
water are added. The organic layer is dried by Na2SO4. After removal of solvent, white solid 
3.34 is obtained as product. 
Benzyl ((S)-1-(((S)-3-(4-fluorophenyl)-1-(((S)-1-hydroxy-3-morpholinopropan-2-yl) 
amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate is dissolved in 
DMSO/ DCM at 0 °C. DIEA and SO3-Pyr are added. After 1 hour, the first step is complete. 
(2-oxotetrahydrofuran-3-yl)triphenylphosphonium, Bromide is added. The temperature is 
increased to r.t. After 1 hour, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. HPLC (C18, 
10-90% ACN: Water, 0.1% F.A.) is applied to purified the product 3.13. Yield is 21.6%. 
Synthesis of compound 3.14 
N
H
H
N
F
O
N
H
OH
O
O
O
O
O
 
(5S,8S,11S)-methyl-8-(4-fluorobenzyl)-11-(hydroxymethyl)-5-isopropyl-3,6,9-trioxo-1-
phenyl-2-oxa-4,7,10-triazadodecan-12-oate and imidazole are dissolved in DMF at 0 °C, then 
TBDMS-Cl is added. The reaction is warmed up to r.t. After over night, the reaction is 
complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
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organic layer is dried by Na2SO4. The product 3.35 is purified by column (0-70%, EA: HX). 
(5S,8S,11S)-Methyl-11-(((tert-butyldimethylsilyl)oxy)methyl)-8-(4-fluorobenzyl)-5 
-isopropyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/ 
MeOH at 0 °C. LiBH4 solution is slowly added.After 30 mins, the reaction is complete. The 
solvent is removed. Pale yellow solid is collected as crude prodcut 3.36 which is directly used 
for next step. 
Benzyl((6R,9S,12S)-9-(4-fluorobenzyl)-6-(hydroxymethyl)-2,2,3,3,13-pentamethyl-8,11 
-dioxo-4-oxa-7,10-diaza-3-silatetradecan-12-yl)carbamate is dissloved in DMSO/DCM at 
0 °C. DIEA is added. Then SO3-Pyr is added. After 30 mins, the first step is complete. Then 
(2-oxotetrahydrofuran-3-yl)triphenylphosphonium, Bromide is added. After 1hour, the 
reaction is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. 
The organic layer is dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, 10-90% ACN: Water, 0.1% F.A.). Compound 3.37 is obtained. Yield is 50.8%. 
Benzyl((6R,9S,12S)-9-(4-fluorobenzyl)-2,2,3,3,13-pentamethyl-8,11-dioxo-6-((E)-(2-ox
odihydrofuran-3(2H)-ylidene)methyl)-4-oxa-7,10-diaza-3-silatetradecan-12-yl)carbamate is 
dissolved in THF. TBAF is added. After 20 mins, the reaction is complete. HPLC is applied 
to purify the product 3.14 (C18, 10-90% ACN:Water, 0.1% F.A.). Yield is 58.1%. 
 
 
 
Synthesis of compound 3.15 
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Ethyl 2-((tert-butoxycarbonyl)amino)-3-(2-hydroxypyridin-3-yl)propanoate is dissolved 
in HCl/dioxane. After 30 mins, the reaction is complete. LCMS shows two stereoisomers. 
After removal of solvent, the white solid 3.38 is collected as crude product for next step 
directly. 
(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl) 
propanoic acid and ethyl 2-amino-3-(2-hydroxypyridin-3-yl)propanoate, Hydrochloride are 
dissolved in DMF at 0 °C. DIEA is added. T3P is added slowly. After 20 mins, the reaction is 
complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. After removal of solvent, pale yellow solid 3.39 is 
collected as crude product for next step. 
(5S,8S)-Ethyl-8-(4-fluorobenzyl)-11-((2-hydroxypyridin-3-yl)methyl)-5-isopropyl-3,6,9
-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in MeOH/THF at 0 °C. 
LiBH4 (3 eq) is added. After 2 days, more LiBH4 (5eq) is added, but the reaction is still not 
complete. After 3 days, the reaction is almost done. The solution is diluted by 40 mL EA and 
washed by NaHCO3 and brine. Some white solid precipitates out. It is collected by filtration 
and washed by water. The organic layer is dried by Na2SO4. After removal of solvent, the 
residue is washed by ether. The solid 3.40 is collected by filtration and combined to the first 
one. 
Benzyl((2S)-1-(((2S)-3-(4-fluorophenyl)-1-((1-hydroxy-3-(2-hydroxypyridin-3-yl) 
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propan-2-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate is 
dissolved in DCM/DMSO at 0 °C. DIEA is added. SO3-Pyr is added. After 40 mins, LCMS 
shows the first step is complete. (2-oxotetrahydrofuran-3-yl)triphenylphosphonium, Bromide 
is added. After over night, the reaction is complete. The solution is diluted by 30 mL EA and 
washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.15 is obtained. Yield is 58.3%. 
Synthesis of compound 3.16, 3.44 
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(S)-3-(1-((allyloxy)carbonyl)piperidin-4-yl)-2-((tert-butoxycarbonyl)amino)propanoic 
acid is dissolved in HCl (4 N)/dioxane and methanol. The reaction is kept for over night. 
LCMS shows the reaction is complete. After removal of solvent, white solid is collected for 
next step directly. 
(S)-Allyl 4-(2-amino-3-methoxy-3-oxopropyl)piperidine-1-carboxylate, Hydrochloride 
and (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl) 
propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is added slowly. After 20 
mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, white solid 3.42 is 
 116 
 
collected as crude product for next step directly. 
Allyl-4-((5S,8S,11S)-8-(4-fluorobenzyl)-5-isopropyl-11-(methoxycarbonyl)-3,6,9-trioxo
-1-phenyl-2-oxa-4,7,10-triazadodecan-12-yl)piperidine-1-carboxylate is dissolved in 
THF/MeOH at 0 °C. LIBH4 solution is slowly added. After 1 hour, the reaction is complete. 
The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, crude product 3.43 is directly used in next step. 
Allyl-4-((5S,8S,11S)-8-(4-fluorobenzyl)-11-(hydroxymethyl)-5-isopropyl-3,6,9-trioxo-1
-phenyl-2-oxa-4,7,10-triazadodecan-12-yl)piperidine-1-carboxylate is dissolved in DMSO/ 
DCM at 0 °C. DIEA is added. SO3-pyr is added after 5 mins. The reaction is kept in 0 °C for 
1 hour. LCMS shows the first step is complete. (2-oxotetrahydrofuran-3-yl)triphenyl 
phosphonium, Bromide is added. The reaction is warmed up to r.t. after 20 mins. Then it is 
stirred for over night. LCMS shows the reaction is complete. The solution is diluted by 30 mL 
EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal 
of solvent, the residue is purified by HPLC (C18, reverse phase, 10-90% ACN/H2O). White 
solid 3.16 is collected. Yield is 43.5%. 
Allyl 4-((5S,8S,11S)-8-(4-fluorobenzyl)-5-isopropyl-3,6,9-trioxo-11-((E)-(2-oxodihydro 
furan-3(2H)-ylidene)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-yl)piperidine-1-carbox
ylate is dissolved in DCM. Morphline and Pd(PPh3)4 are added. 10% catalyst is added first. 
But after 4 hours, the reaction is still not complete. Another 20% catalyst is added. The 
reaction is complete in 20 mins. After removal of solvent, HPLC (C18, reverse phase, 
10-90%, ACN/H2O) is applied to purify the residue.  Compound 3.44 is obtained. Yield is 
33.7%. 
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Synthesis of compound 3.17 
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Ethyl 2-amino-3-(2-methoxypyridin-3-yl)propanoate and (S)-2-((S)-2-(((benzyloxy) 
carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl)propanoic acid are dissolved in 
DMF at 0 °C. DIEA is added. T3P is added slowly. After 20 mins, LCMS shows the reaction 
is complete. The solution is diluted by 30 mL EA and washed by HCl, NaHCO3 and brine. 
The organic layer is dried by NA2SO4. After removal of solvent, white solid 3.39 is collected 
as crude product which is directly used in next step. 
(5S,8S)-ethyl-8-(4-fluorobenzyl)-5-isopropyl-11-((2-methoxypyridin-3-yl)methyl)-3,6,9
-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/MeOH at 0 °C. 
LiBH4 solution is added slowly. After 40 mins, the reaction is complete. 30 mL EA is added 
to the solution. The mixture is washed by HCl, NaHCO3 and brine. The organic layer is dried 
by Na2SO4. After removal of solvent, white solid 3.41 is collected as crude product for next 
step directly. 
Benzyl((2S)-1-(((2S)-3-(4-fluorophenyl)-1-((1-hydroxy-3-(2-methoxypyridin-3-yl)propa
n-2-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate is dissolved in 
DCM/DMSO at 0°C. DIEA and SO3-pyr is added. After 1 hour, the first step is done. 
(2-oxotetrahydrofuran-3-yl)triphenylphosphonium, Bromide is added. The reaction is kept in 
0 °C for 20 mins and then warmed up tp r.t. After 3 days, the reaction is still not complete. 
The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
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dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2)). Two isomers are collected. Both are white solid. Retention times 
are 0.90 and 0.91 mins respectively. The first one is compound 3.17. Yield is 39%. 
Synthesis of compound 3.18 
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(S)-Methyl 2-amino-3-(4-fluorophenyl)propanoate and (S)-2-(((benzyloxy)carbonyl) 
amino)-3-methylbutanoic acid are dissolved in DMF. DIEA is added at 0 °C. Then T3P is 
added dropwised. The reaction is kept at 0 °C for one hour. Then 150 mL EA is added. The 
solution is washed by NaHCO3 (twice), brine (twice). The organic layer is dried by Na2SO4. 
After removal of the solvent, white solid is formed as product 3.22. 
(S)-Methyl-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluoroph
enyl) propanoate is dissolved in THF/MeOH/Water (6:2:2). LiOH (1.2 eq) is added in room 
temperature. After 20 min, the reaction is complete. The solution is acidified by using 1M 
HCl to pH 3-4. The organic solvent is removed. White solid forms. 5 mL water is added. The 
product 3.23 is filtered by vacuum and washed by ether. 
(S)-4-((tert-butoxycarbonyl) amino)-5-methoxy-5-oxopentanoic acid is dissolved in 8 
mL DMF. DIEA and HATU are added at 0 °C. After 10 mins, DMA is added dropwised. After 
40 mins, the reaction is complete (TLC EA:HX=3:1, Rf=0.2, ninhydrin). The solution is 
diluted by 50 mL EA. Then it is washed by citric acid (10%, twice), NaHCO3 (twice), brine. 
The organic layer is dried by Na2SO4 and concentrated by vacuum. Ethyl acetate and ether 
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are used to crystallize the product 3.20 as solid. 
(S)-Methyl 2-((tert-butoxycarbonyl) amino)-5-(dimethylamino)-5-oxopentanoate is 
dissolved in HCl solution. After half hour, the reaction is complete. After removal of the 
solvent, the crude product 3.21 is directly used for next step without further purification. 
(S)-methyl 2-amino-5-(dimethylamino)-5-oxopentanoate and (S)-2-((S)-2-(((benzyloxy) 
carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl)propanoic acid are dissolvedin 
DMF with DIEA at 0 °C. Then T3P is added dropwised. After 30 mins, the reaction is 
complete. The solution is diluted by 50 mL EA and washed by NaHCO3 (twice), brine 
(twice). After removal of most solvent, white solid is precipitated out as product 3.24. 
(5S,8S,11S)-Methyl 11-(3-(dimethylamino)-3-oxopropyl)-8-(4-fluorobenzyl)-5-isopropy 
l-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/MeOH at 
0 °C. LiBH4 solution is added slowly. After 30 mins, the reaction is complete. 10 mL 
NaHCO3 solution is added to quench the reaction. Then 10 mL water and 50 mL EA are 
added. The organic layer is collected and dried by Na2SO4. After removal of the solvent, 
white solid is formed as the product 3.25. 
Benzyl((S)-1-(((S)-1-(((S)-5-(dimethylamino)-1-hydroxy-5-oxopentan-2-yl)amino)-3-(4
-fluorophenyl)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate is dissolved in 
DMSO and DCM at 0 °C.DIEA is added. Then sulfur trioxide pyridine complex is added. 
After 30 mins, the first step is complete. Then (2-oxotetrahydrofuran-3-yl) 
triphenylphosphonium, Bromide is added. The reation is warmed up to room temperature. 
After 1 hour, the reaction is complete which comfirmed by LCMS. 20 mL brine and 20 mL 
EA are added to the reaction. White solid 3.18 precipitates out. It's collected by filtration. 
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Synthesis of compound 3.31 
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(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanamido)-3-(4-fluorophenyl)pro
panoic acid is dissolved in 3 mL DMF. 2 eq DIEA is added. Let the activation go for 10 mins. 
Then it is slowly added to the solution of (S)-methyl-2-amino-3-(1H-imidazol 
-4-yl)propanoate, 2Hydrochloride and 3 eq DIEA in 3 mL DMF. After 1.5 hours, the reaction 
is complete. The solution is diluted by 30 mL EA and washed by citric acid, NaHCO3 and 
brine. The organic layer is dried by Na2SO4. After removal of the solvent, the residue is 
washed by diethyl ether. The pale yellow solid 3.28 is collected by filtration. 
(5S,8S,11S)-Methyl-11-((1H-imidazol-4-yl)methyl)-8-(4-fluorobenzyl)-5-isopropyl 
-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate is dissolved in THF/Methanol at 
0°C. LiBH4 solution is added slowly. After 1.5 hours, the reaction is complete. 30 mL EA is 
added to the solution. The mixture is washed by brine. The organic layer is dried by Na2SO4. 
After removal of solvent, white solid 3.30 is collected as product. 
Benzyl((S)-1-(((S)-3-(4-fluorophenyl)-1-(((S)-1-hydroxy-3-(1H-imidazol-4-yl)propan-2-
yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate is dissolved in 
DCM/ DMSO at 0 °C. DIEA and SO3-Pyr are added. After 1.5 hours, the first step is 
complete.(2-oxotetrahydrofuran-3-yl)triphenylphosphonium, Bromide is added and the 
reaction is increased to room temperature. After over night, the reaction is complete. Solution 
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is diluted by 50 mL EA and washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of the solvent, the residue is purified by HPLC. Compound 3.31 is 
obtained. 
Synthesis of compound 3.45 
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Tert-butyl((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-
2-yl)carbamate is dissolved in HCl/dioxane. After stirring for 15 mins, the reaction is 
complete. The solvent is taken off and the residue is dried by vacuum for 2 hours. The residue 
is dissolved in DMF at 0 °C. (S)-2-((tert-butoxycarbonyl)amino) -3-(pyridin-4-yl)propanoic 
acid and DIPEA are added. T3P solution is added slowly. After 20 mins, the reaction is 
complete. The mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. After removal of solvent, the residue 3.67 is used in next 
step directly. 
Tert-butyl((2S)-1-(((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3-
yl)butan-2-yl)amino)-1-oxo-3-(pyridin-4-yl)propan-2-yl)carbamate is dissolved in HCl/ 
dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and the 
residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0°C. 
2-(((benzyloxy) carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA are added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
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After removal of solvent, the residue 3.69 is used in next step directly. 
Benzyl(1-(((2S)-1-(((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3
-yl)butan-2-yl)amino)-1-oxo-3-(pyridin-4-yl)propan-2-yl)amino)-3-(4-fluorophenyl )-1-oxo 
propan-2-yl)carbamate is dissolved in DCM. Dess-martin reagent is added. The mixture is 
sonicated for 2 mins. Then the reaction is stirred in room temperature for 40 mins. The 
reaction is monitored by LCMS. After it's complete, the mixture is directly loaded onto a 
silica columm and purified by DCM/2-propanol, 0-60%. Product 3.45 is obtained. Yield is 
72.9%. 
Synthesis of compound 3.46 
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Tert-butyl((2S)-1-(((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3-
yl)butan-2-yl)amino)-1-oxo-3-(pyridin-4-yl)propan-2-yl)carbamate is dissolved in HCl/ 
dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and the 
residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0°C. 
(S)-2-((tert-butoxycarbonyl) amino)-3-(dimethylamino)propanoic acid and DIPEA are added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is 3.68 used in next step directly. 
Tert-butyl((2S)-1-(((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3-
yl) butan-2-yl)amino)-3-(dimethylamino)-1-oxopropan-2-yl)carbamate is dissolved in HCl/ 
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dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and the 
residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0°C. 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA are added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue 3.70 is used in next step directly. 
Benzyl((2S)-1-(((2S)-1-(((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxo 
pyrrolidin-3-yl) butan-2-yl)amino)-3-(dimethylamino)-1-oxopropan-2-yl)amino)-3 -(4-fluoro 
phenyl)-1-oxopropan-2-yl)carbamate is dissolved in DCM. Dess-martin reagent is added. The 
mixture is sonicated for 2 mins. Then the reaction is stirred in room temperature for 40 mins. 
The reaction is monitored by LCMS. After it's complete, the mixture is directly loaded onto a 
silica columm and purified by DCM/2-propanol, 0-60%. Product 3.46 is obtained. Yield is 
27%. 
 
 
Synthesis of compound 3.47 
N
H
NH
H
O
O
O
OH
N
CbzHN
O
 
(S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanoic acid and (S)-3-((S,E)-2-amino- 
3-(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one, Hydrochloride are dissolved in 
DMF at 0 °C. DIEA is added. T3P is added slowly. After 30 mins, the reaction is complete. 
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The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, the residue 3.57 is directly used in next step. 
Tert-butyl ((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamate is dissolved in 
HCl/dioxane. After 20 mins, the reaction is complete. After removal of solvent, crude product 
3.58 is collected for next reaction directly. 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-(((benzyloxy)carbonyl) 
amino)-3 -phenylpropanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA and 
washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90% ACN/H2O). Product 
3.47 is obtained. Yield is 39.2%. 
 
Synthesis of compound 3.48 
N
H
NH
O
O
O
H
N
O
CbzHN
O
 
Tf2O is added to pyridine in pentane solution at 0 °C. It forms white/pink solid. After 
stirred for 1 hour, cyclopent-3-en-1-ylmethanol in pentane solution is added to the reaction 
slowly. The reaction is kept for another 1.5 hours in ice bath. Then the mixture is filtered by 4 
g aluminum oxide and washed by 20 mL pentane. After removal of solvent, colorless oil is 
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collected as product 3.63. NMR shows clean. 
(2R,3S)-Tert-butyl 6-oxo-2,3-diphenylmorpholine-4-carboxylate is dissolved in 
THF/HMPA and cooled to -78 °C. NaHMDS solution is added and kept for 30 mins. 
Cyclopent-3-en-1-ylmethyl trifluoromethanesulfonate is dissolved in 3 mL THF and added 
dropwised to the reaction. The reaction is kept for 2 hours. Then it is warmed up to room 
temperature. The mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4 and purified by column (normal phase, silica gel, 0-60%, 
EA/HX). Compound 3.64 is obtained. Yield is 45.2%. 
Liquid ammonia is condensed by dryice/acetone.The three-neck flask is cooled to -78 °C 
and protected by N2. After about 20 mL liquid ammonia is collected, lithium metal is added. 
The solution turns dark blue. Let the mixture stir for 30 mins. The solution of 
(3S,5S,6R)-tert-butyl-3-(cyclopent-3-en-1-ylmethyl)-2-oxo-5,6-diphenylmorpholine-4-carbo
xylate in THF and ethanol is added. The reaction is kept under -78 °C for 2 hours. LCMS 
shows the reaction is complete. 5 mL methanol is slowly added to quench the reaction. Then 
the mixture is acidified by diluted HCl (1 M) to pH 2. The solution is extracted by EA (20 mL) 
twice. The organic layer is dried by Na2SO4. After removal of solvent, the residue 3.65 is 
directly used in next step. 
(S)-3-((S,E)-2-amino-3-(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one, 
Hydrochloride is dissolved in DMF at 0 °C with DIPEA and 
(S)-2-((tert-butoxycarbonyl)amino)-3-(cyclopent-3-en-1-yl)propanoic acid. T3P is added 
slowly. After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) and 
washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
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solvent, compound 3.66 is directly used in next step. 
Tert-butyl((S)-3-(cyclopent-3-en-1-yl)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylid
ene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate is dissolved in 
HCl/dioxane. After stirred for 20 mins, the reaction is complete. After removal of solvent, the 
residue is dried by vacuum and directly used in next step. 
(S)-2-amino-3-(cyclopent-3-en-1-yl)-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-(
(S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide, Hydrochloride is dissolved in DMF at 
0 °C with DIPEA and (S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid. 
T3P is added slowly. After 15 mins, the reaction is complete. The mixture is diluted by EA 
(30 mL) and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, it is purified by HPLC (reverse phase, C18, 10-90%, ACN/H2O). 
Compound 3.48 is obtained. Yield is 26.2%. 
 
Synthesis of compound 3.50 
CbzHN
F
O
N
O N
H
NH
O
O
O  
(2S,4R)-1-(tert-butoxycarbonyl)-4-phenylpyrrolidine-2-carboxylic acid and (S)-3- 
((S,E)-2-amino-3-(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one are dissolved in 
DMF at 0 °C. DIEA is added. T3P is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue 3.71 is used in 
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next step directly. 
(2S,4R)-Tert-butyl 2-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)carbamoyl)-4-phenylpyrrolidine-1-carboxylate is dissolved in 
HCl/ dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and 
the residue is dried by vacuum for 2 hours. The residue 3.76 is dissolved in DMF at 0°C. 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA are added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is purified by HPLC (reverse phase, C18, 10-90%, 
ACN/H2O). Compound 3.50 is obtained. Yield is 35.1%. 
 
 
Synthesis of compound 3.51 
N
O
Ph
N
H
NH
O
O
O
CbzHN
F
O
 
(S)-2-((tert-butoxycarbonyl) amino)-3-(4-((cyclohexyloxy)carbonyl)phenyl)propanoic 
acid and (S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3 -((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA 
is added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to 
the solution. The solution is washed by NaHCO3 and brine. The organic layer is collected 
and dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (reverse 
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phase, C18, 10-90% ACN/H2O). Compound 3.51 is obtained. Yield is 22.88%. 
Synthesis of compound 3.52 
N
O NH
NH
O
O
O
Ph
CbzHN
F
O
 
(2S,3S)-1-(tert-butoxycarbonyl)-3-phenylpyrrolidine-2-carboxylic acid and (S)-3- 
((S,E)-2-amino-3-(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one are dissolved in 
DMF at 0 °C. DIEA is added. T3P is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue 3.73 is used in 
next step directly. 
Starting material is from a racemic cis DL proline precursor. It is dissolved in 
HCl/dioxane. After 10 mins, the reaction is complete. After removal the solvent, the residue 
3.78 is dried by vacuum and directly used in next step. The residue is dissolved in DMF at 
0°C. (S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA are 
added. T3P is added slowly. After 20 mins the reaction is complete. After diluted by 30 mL 
EA, the mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is purified by HPLC (reverse phase, C18, 10-90%, 
ACN/H2O). The product 3.52 is a mixture of cis DL on proline. Yield is 44.3%. 
Synthesis of compound 3.56 
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N
O
N
H
H
N
O
O
O
CF3
CbzHN
F
O
 
(2S,4S)-Tert-butyl-2-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)carbamoyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate is 
dissolved in HCl/dioxane. After stirred for 20 mins, the reaction is complete. After removal of 
solvent, the residue 3.79 is dried by vacuum and directly used in next step. 
(2S,4S)-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)pro
pan-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide, Hydrochloride is dissolved in DMF 
at 0 °C.(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA 
are added. T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture 
is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by HPLC (reverse phase, C18, 
10-90%, ACN/H2O). Compound 3.56 is obtained. Yield is 42%. 
Synthesis of compound 3.59 
H
N
N
H
H
NO
O
CbzHN
F
O
F
F
O
O
 
(2S)-2-amino-3-(3,3-difluorocyclopentyl)propanoic acid, Hydrochloride is dissolved in 
dioxane/water. NaHCO3 is added. Boc-anhydride is dissolved in dioxane and added to the 
reaction. After 1 hour, the reaction is complete. 30 mL EA is added to the solution. The 
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mixture is washed by 1 M HCl and brine. The organic layer is collected and dried by Na2SO4. 
After removal of solvent, the residue is directly used in next step. 
(2S)-2-((tert-butoxycarbonyl) amino)-3-(3,3-difluorocyclopentyl)propanoic acid is 
dissolved in DMF at 0 °C with DIPEA and (S)-3-((S,E)-2-amino-3- 
(2-oxodihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one, Hydrochloride. T3P is added 
slowly. After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) and 
washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, compound 3.60 is dried by vacuum and directly used in next step. 
Tert-butyl((2S)-3-(3,3-difluorocyclopentyl)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H) 
-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate is dissolved 
in HCl/dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off 
and the residue 3.61 is dried by vacuum for 2 hours. The residue is dissolved in DMF at 
0 °C.(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and DIPEA are 
added. T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is 
diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by HPLC (reverse phase, C18, 
10-90%, ACN/H2O). Compound 3.59 is obtained. Yield is 6.1%. 
Synthesis of compound 3.62 
N
H
NH
O
O
O
H
N
O
CbzHN
O
 
(S)-2-amino-3-(cyclopent-3-en-1-yl)-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-(
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(S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide, Hydrochloride is dissolved in DMF at 
0 °C with DIPEA and (S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanoic acid. T3P is 
added slowly. After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, it is purified by HPLC (reverse phase, C18, 10-90%, ACN/H2O). Compound 3.62 is 
obtained. Yield is 31.2%. 
Synthesis of compound 3.81 
H
N
O
N
H
H
N
O
O
O
O
O
O
 
Tert-butyl((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrol
idin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamate is dissolved in HCl /dioxane. 
After 20 mins, the reaction is complete. After removal of solvent, crude product is collected 
for next reaction directly. 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-(((benzyloxy) carbonyl)amino) 
-3-phenylpropanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is added slowly. 
After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90% ACN/H2O). Compound 3.81 is 
obtained. Yield is 39.2%. 
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Synthesis of compound 3.82 
H
N
O
N
H
H
N
O
O
O
O
O
O
NH
 
Tert-butyl((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo-pyrro
lidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamate is dissolved in HCl/ dioxane. 
After 30 mins, the reaction is complete. After removal of solvent, the residue is washed by 
diethyl ether. Yellow solid is collected via filtration for next step directly. 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-(((benzyloxy) 
carbonyl)amino)-3- (1H-indol-3-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.82 is obtained. 
Yield is 12%. 
Synthesis of compound 3.83 
H
N
O
N
H
H
N
O
O
O
O
O
O
N
 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
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)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-((tertbutoxycarbonyl) 
amino)-3- (pyridin-4-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. After removal of solvent, the residue is directly used in 
next step. 
Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(pyridin-4-yl) 
propa n-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, white solid is collected for next step directly. 
(S)-2-amino-N-((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo
pyrrolidin-4-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)-3-(pyridin-3-yl)propanamide, 
2Hydrochloride is dissolved in DMF at 0 °C. DIEA is added, CbzCl is added slowly. After 20 
mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90% ACN/H2O). Compound 3.83 is obtained. 
Yield is 36.1%. 
Synthesis of compound 3.84 
H
N
O
N
H
H
N
O
O
O
O
O
O
N
 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
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)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-((tertbutoxycarbonyl) 
amino)-3- (pyridin-3-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. After removal of solvent, the residue is directly used in 
next step. 
Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(pyridin-3-yl)pro
pan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, white solid is collected for next step directly. 
(S)-2-amino-N-((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo
pyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)-3-(pyridin-3-yl)propanamide, 
2Hydrochloride is dissolved in DMF at 0 °C. DIEA is added, CbzCl is added slowly. After 20 
mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90% ACN/H2O). Compound 3.84 is obtained. 
Yield is 35%. 
Synthesis of compound 3.85 
H
N
O
N
H
H
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O
O
O
O
O
O
 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
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)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-(((benzyloxy)carbonyl) 
amino)-4- methylpentanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic 
layer is dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, 
reverse phase, 10-90%, ACN/H2O). Compound 3.85 is obtained. Yield is 44.9%. 
Synthesis of compound 3.86 
H
N
O
N
H
H
N
O
O
O
O
O
O
 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(naphthalen-2-yl)propanoic acid and (2S)-2- 
amino-3-(4-fluorophenyl)-N-((2S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-(2-oxopyrrolidi
n-3-yl)propan-2-yl)propanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. After 30 mins, the reaction is complete. The solution is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, 
ACN/H2O). Compound 3.86 is obtained. Yield is 43.9%. 
Synthesis of compound 3.87 
H
N
O
N
H
H
N
O
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O
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O
N
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(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl
)propan-2-yl)-3-phenylpropanamide, Hydrochloride and (S)-2-(((benzyloxy)carbonyl)amino) 
-3-(1-methyl-1H-indol-2-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. After 15 mins, the reaction is complete. 30 mL EA is added to the 
solution. The mixture is washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse phase, 
10-90%, ACN/H2O). Compound 3.87 is obtained. Yield is 30.3%. 
Synthesis of compound 3.88 
H
N
O
N
H
H
N
O
O
O
O
O
O
 
(S)-3-([1,1'-biphenyl]-3-yl)-2-aminopropanoic acid is dissolved in DMF in 0 °C. DIEA 
is added. Cbz-Cl is added slowly. After 15 mins, LCMS shows very messy peaks. There is no 
starting material left. So the reaction is worked up. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent,the residue is used in next step directly. 
(S)-3-([1,1'-biphenyl]-3-yl)-2-(((benzyloxy)carbonyl)amino)propanoic acid and 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl )pro
pan-2-yl)-3-phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
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dried by Na2SO4. After removal of solvent,the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.88 is obtained. Yield is 10.56%. 
Synthesis of compound 3.89 
H
N
O
N
H
H
N
O
O
O
O
O
O
OO
 
(S)-2-amino-3-(benzo[d][1,3]dioxol-5-yl)propanoic acid is dissolved in dioxane/water. 
NaHCO3 is added. Then the solution is cooled to 0 °C. Cbz-Cl is added. After 15 mins, the 
reaction is complete. 30 mL EA is added to the solution. The mixture is washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, the residue is used 
for next step directly. 
(S)-3-(benzo[d][1,3]dioxol-5-yl)-2-(((benzyloxy)carbonyl)amino)propanoic acid and 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)prop
an-2-yl)-3-phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent,the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.89 is obtained. Yield is 14.81%. 
Synthesis of compound 3.90 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(quinolin-2-yl)propanoate is dissolved in 
THF/MeOH/Water. LiOH is added. After 20 mins, the reaction is complete. The solution is 
neutralized by HCl/dioxane. After removal of solvent, the residue is directly used for next 
step. 
(S)-2-((tert-butoxycarbonyl) amino)-3-(quinolin-2-yl)propanoic acid and (S)-2-amin 
o-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3-
phenyl propanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is directly used in next step. 
Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(quinolin-2-yl) 
propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. The, it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 15 mins, the reaction is done. 30 
mL EA is added to the solution. The mixture is washed by NaHCO3 and brine. The organic 
layer is dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, 
reverse phase, 10-90%, ACN/H2O). Compound 3.90 is obtained. Yield is 23.4%. 
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Synthesis of compound 3.91 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(quinolin-6-yl)propanoate is dissolved in 
HCl/dioxane. After 15 mins, the reaction is complete. After removal of solvent, the residue is 
dried by vacuum for 30 mins. Then it is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is 
added slowly. After 15 mins, the reaction is done. 30 mL EA is added to the solution. The 
mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is used in next step directly. 
(S)-Methyl 2-(((benzyloxy)carbonyl)amino)-3-(quinolin-6-yl)propanoate is dissolved in 
THF/MeOH/H2O. LiOH is added. After 15 mins, the reaction is complete. The solution is 
neutralized by HCl/dioxane. After removal all the solvent, the residue is washed by EA. After 
filtration, the filtrate is concentrated and directly used in next step. 
(S)-2-(((benzyloxy) carbonyl)amino)-3-(quinolin-6-yl)propanoic acid and (S)-2-amino 
-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-
phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent,the residue is purified by HPLC (C18, reverse phase, 
10-90%, ACN/H2O). Compound 3.91 is obtained. Yield is 24.46%. 
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Synthesis of compound 3.92 
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(S)-2-((tert-butoxycarbonyl)amino)-4,4,4-trifluorobutanoic acid and (S)-2-amino-N- 
((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3- 
phenyl propanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl((S)-4,4,4-trifluoro-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H
)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino) 
butan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent,the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.92 is obtained. 
Yield is 64.9%. 
Synthesis of compound 3.93 
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(S)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid and (S)-2-amino-N- 
((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-phe
nyl propanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-
ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)propan
-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, ther residue is dried by vacuum for 30 mins. 
Then it is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The 
reaction is complete after 20 mins. 30 mL EA is added to the solution. The solution is washed 
by NaHCO3 and brine. The organic layer is collected and dried by Na2SO4. After removal of 
solvent,the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.93 is obtained. Yield is 57%. 
Synthesis of compound 3.94 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(3-methoxyphenyl)propanoate is dissolved 
in THF/MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The solution is 
diluted by 30 mL EA and washed by HCl (1M) and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is used for next step directly. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(3-methoxyphenyl)propanoic acid and (S)-2- 
amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)-3 -phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-(3-methoxyphenyl)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl) 
amino)propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.94 is 
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obtained. Yield is 38.2%. 
Synthesis of compound 3.95 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(3-isopropoxyphenyl)propanoate is 
dissolved in THF/MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The 
solution is diluted by 30 mL EA and washed by HCl (1M) and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, the residue is used for next step directly.  
(S)-2-((tert-butoxycarbonyl)amino)-3-(3-isopropoxyphenyl)propanoic acid and 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)prop
an-2-yl)-3 -phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent,the residue is used in next step directly.  
Tert-butyl ((S)-3-(3-isopropoxyphenyl)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino) -3-phenylpropan-2- 
yl)amino)propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the 
reaction is complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. 
Then it is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is 
complete after 20 mins. 30 mL EA is added to the solution. The solution is washed by 
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NaHCO3 and brine. The organic layer is collected and dried by Na2SO4. After removal of 
solvent,the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.95 is obtained. Yield is 46%.  
Synthesis of compound 3.96 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(2-methoxyphenyl)propanoate is dissolved 
in THF/MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The solution is 
diluted by 30 mL EA and washed by HCl (1M) and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is used for next step directly. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(2-methoxyphenyl)propanoic acid and 
(S)-2-amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)prop
an-2-yl)-3 -phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-(2-methoxyphenyl)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl) 
amino)propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
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dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.96 is 
obtained. Yield is 26.7%. 
Synthesis of compound 3.97 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(o-tolyl)propanoate is dissolved in THF/ 
MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The solution is diluted 
by 30 mL EA and washed by HCl (1M) and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is used for next step directly. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(o-tolyl)propanoic acid and (S)-2-amino-N-((S,E) 
-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3–phenylpro
pan amide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added slowly. 
The reaction is complete after 20 mins. 30 mL EA is added to the solution. The solution is 
washed by NaHCO3 and brine. The organic layer is collected and dried by Na2SO4. After 
removal of solvent,the residue is used in next step directly. 
Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(o-tolyl)propan-2
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-yl )carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF 
at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.97 is obtained. Yield is 
42.9%. 
Synthesis of compound 3.98 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(3-phenoxyphenyl)propanoate is dissolved 
in THF/MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The solution is 
diluted by 30 mL EA and washed by HCl (1M) and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is used for next step directly. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(3-phenoxyphenyl)propanoic acid and (S)-2- 
amino-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)-3 -phenylpropanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
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Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(3-phenoxyphen
yl) propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.98 is 
obtained. Yield is 38.2%. 
Synthesis of compound 3.99 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(1H-indol-3-yl)propanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-y l)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.99 is obtained. Yield is 51.9%. 
Synthesis of compound 3.100 
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(S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanoic acid and (S)-2-(((benzyloxy) 
carbonyl)amino)-4-methylpentanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.100 is obtained. Yield is 51.7%. 
Synthesis of compound 3.101 
H
N
O
N
H
H
N
O
O
O
O
O
O
N
 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride and (S)-2-((tertbutoxycarbonyl) 
amino)-3 -(pyridin-3-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the crude solid is directly used in next step. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(pyridin-3-yl)pro
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pan-2-yl)carbamate is dissolved in HCl/dioxane. After 20 mins, the reaction is complete. 
After removal of solvent, white solid is collected as crude product for next step. 
(S)-2-((S)-2-amino-3-(pyridin-3-yl)propanamido)-4-methyl-N-((S,E)-1-(2-oxodihydrofu
ran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide is dissolved in 
DMF. DIEA is added. CbzCl is added slowly. After 20 mins, LCMS shows some 
bis-Cbz-substituted product formed. The solution is diluted by 30 mL EA and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.101 is 
obtained. Yield is 11.27%. 
Synthesis of compound 3.102 
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(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride and (S)-2-((tertbutoxycarbonyl) 
amino)-3 -(pyridin-4-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is directly used in next step. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(pyridin-4-yl)pro
pa n-2-yl)carbamate is dissolved in HCl/dioxane. After 20 mins, the reaction is complete. 
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After removal of solvent, crude product is collected for next reaction directly. 
(S)-2-((S)-2-amino-3-(pyridin-4-yl)propanamido)-4-methyl-N-((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide is dissolved in 
DMF at 0 °C. DIEA is added, CbzCl is added slowly.After 20 mins, the reaction is complete. 
The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90% ACN/H2O). Compound 3.102 is obtained. Yield is 41.4%. 
Synthesis of compound 3.103 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(naphthalen-2-yl)propanoic acid and (2S)-2- 
amino-4-methyl-N-((2S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-( 2-oxopyrrolidin-3-yl)pr
opan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
Compound 3.103 is obtained. Yield is 54.8%. 
Synthesis of compound 3.104 
 151 
 
H
N
O
N
H
H
N
O
O
O
O
O
O
 
(2S)-2-amino-4-methyl-N-((2S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-(2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride and (S)-2- ((tert-butoxy 
carbonyl)amino)-3-(ptolyl) propanoic acid are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. After 30 mins, the reaction is complete. The solution is diluted by 30 mL EA 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the crude product is directly used in next step. 
Tert-butyl((2S)-1-(((2S)-4-methyl-1-oxo-1-(((2S,E)-1-(2-oxodihydrofuran-3(2H)-yliden
e)-3-(2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(p-tolyl)propan-2
-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, white solid is collected for next step directly.  
(2S)-2-((S)-2-amino-3-(p-tolyl)propanamido)-4-methyl-N-((2S,E)-1-(2-oxodihydrofuran
-3(2H)-ylidene)-3-(2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride is 
dissolved in DMF at 0 °C. DIEA is added, CbzCl is added slowly.After 20 mins, the reaction 
is complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. After removal of solvent, the residue is purified by HPLC 
(C18, reverse phase, 10-90% ACN/H2O). Compound 3.104 is obtained. Yield is 37.1%. 
Synthesis of compound 3.105 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(quinolin-3-yl)propanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene )-3-((S)-2-oxopyrrolidin-3-yl)propa
n-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is directly used in next step. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(quinolin-3-yl) 
propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, the residue is directly used in next reaction. 
(S)-2-((S)-2-amino-3-(quinolin-3-yl)propanamido)-4-methyl-N-((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide, 2Hydrochloride 
is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 15 mins, the 
reaction is complete. 30 mL EA is added to the solution. The solution is washed by NaHCO3 
and brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.105 is 
obtained. Yield is 33.7%. 
Synthesis of compound 3.106 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(quinolin-3-yl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene )-3-((S)-2-oxopyrrolidi
n-3-yl)propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent,the residue is directly used in next step. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(quinolin-2-yl)propanoic acid and (S)-2-amino 
-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3-p
henyl propanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is directly used in next step. 
Tert-butyl((S)-1-oxo-1-(((S)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((
S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-3-(quinolin-2-yl)pr
opan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. The, it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 15 mins, the reaction is done. 30 
mL EA is added to the solution. The mixture is washed by NaHCO3 and brine. The organic 
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layer is dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, 
reverse phase, 10-90%, ACN/H2O). Compound 3.106 is obtained. Yield is 23.4%. 
Synthesis of compound 3.107 
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(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(quinolin-6-yl)propanoate is dissolved in 
HCl/dioxane. After 15 mins, the reaction is complete. After removal of solvent, the residue is 
dried by vacuum for 30 mins. Then it is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is 
added slowly. After 15 mins, the reaction is done. 30 mL EA is added to the solution. The 
mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is used in next step directly. 
(S)-Methyl 2-(((benzyloxy)carbonyl)amino)-3-(quinolin-6-yl)propanoate is dissolved in 
THF/MeOH/H2O. LiOH is added. After 15 mins, the reaction is complete. The solution is 
neutralized by HCl/dioxane. After removal all the solvent, the residue is washed by EA. After 
filtration, the filtrate is concentrated and directly used in next step. 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(quinolin-6-yl)propanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
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Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse phase, 
10-90%, ACN/H2O). Compound 3.107 is obtained. Yield is 42.2%. 
Synthesis of compound 3.108 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(1H-indol-2-yl)propanoic acid and MeI are 
dissolved in DMF at 0 °C. NaH is added. After 15 mins, the reaction is complete. 30 mL EA 
is added to the solution. The mixture is washed by HCl (1 N) twice. The organic layer is dried 
by Na2SO4. After removal of solvent, the crude product is used for next step directly. 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride and (S)-2-(((benzyloxy)carbonyl) 
amino) -3-(1-methyl-1H-indol-2-yl)propanoic acid are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. After 15 mins, the reaction is complete. 30 mL EA is added to 
the solution. The mixture is washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse phase, 
10-90%, ACN/H2O). Compound 3.108 is obtained. Yield is 53.4%. 
Synthesis of compound 3.109 
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(S)-3-([1,1'-biphenyl]-3-yl)-2-(((benzyloxy)carbonyl)amino)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.109 is obtained. Yield is 17.65%. 
Synthesis of compound 3.110 
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(S)-2-amino-3-(benzo[d][1,3]dioxol-5-yl)propanoic acid is dissolved in DMF in 0 °C. 
DIEA is added. Cbz-Cl is added slowly. After 15 mins, LCMS shows very messy peaks. 
There is no starting material left. So the reaction is worked up. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent,the residue is used in next step directly. 
(S)-3-(benzo[d][1,3]dioxol-5-yl)-2-(((benzyloxy)carbonyl)amino)propanoic acid and 
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(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S )-2-oxopyrrolidi
n-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.110 is obtained. Yield is 10.05%. 
Synthesis of compound 3.111 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-isopropoxyphenyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.111 is obtained. Yield is 52.3%. 
 
Synthesis of compound 3.112 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-(tert-butoxy)phenyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O). Compound 3.112 is obtained. Yield is 46.5%. 
Synthesis of compound 3.113 
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(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-(cyclopentyloxy)phenyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene )-3-((S)-2-oxopyrrolidi
n-3-yl)propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is purified by HPLC (C18, reverse 
 159 
 
phase, 10-90%, ACN/H2O). Compound 3.113 is obtained. Yield is 35.3%. 
Synthesis of compound 3.114 
H
N
O
N
H
H
N
O
O
O
O
O
O
O
O
 
(S)-3-(4-acetoxyphenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid and (S)-2- 
amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene )-3-((S)-2-oxopyrrolidin-3-yl)
propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is directly used in next step. 
4-((S)-2-((tert-butoxycarbonyl)amino)-3-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydr
ofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-
oxopropyl)phenyl acetate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, the residue is directly used in next reaction. 
4-((S)-2-amino-3-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-
3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-oxopropyl)phenyl 
acetate, Hydrochloride in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 15 
mins, the reaction is complete. 30 mL EA is added to the solution. The solution is washed by 
NaHCO3 and brine. The organic layer is collected and dried by Na2SO4. After removal of 
solvent,the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). 
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Compound 3.114 is obtained. Yield is 39.9% 
Synthesis of compound 3.115 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(4-propoxyphenyl)propanoic acid and (S)-2- 
amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene )-3-((S)-2-oxopyrrolidin-3-yl)
propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is directly used in next step. 
Tert-butyl ((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene) 
-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(4-propoxyphen
yl )propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, the residue is directly used in next reaction. 
(S)-2-((S)-2-amino-3-(4-propoxyphenyl)propanamido)-4-methyl-N-((S,E)-1-(2-oxodihy
drofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide, 
Hydrochloride is dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 15 
mins, the reaction is complete. 30 mL EA is added to the solution. The solution is washed by 
NaHCO3 and brine. The organic layer is collected and dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). ). 
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Compound 3.115 is obtained. Yield is 46.6%. 
Synthesis of compound 3.116 
H
N
O
N
H
H
N
O
O
O
O
O
O
F
F
 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4-difluorophenyl)propanoic 
acid and (S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3 -((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA 
is added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to 
the solution. The solution is washed by NaHCO3 and brine. The organic layer is collected 
and dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
(9H-fluoren-9-yl) methyl ((S)-3-(3,4-difluorophenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E) 
-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan
-2-y l)amino)-1-oxopropan-2-yl)carbamate is dissolved in 20% piperidine in DMF. After 20 
mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by water 
twice. The aqueous layer is combined and extracted by 5 mL EA. The organic layers is 
combined and dried by Na2SO4. After removal of solvent, the white solid is used in next step 
directly. 
(S)-2-((S)-2-amino-3-(3,4-difluorophenyl)propanamido)-4-methyl-N-((S,E)-1-(2-oxo 
dihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pentanamide is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
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brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.116 is 
obtained. Yield is 55.9%. 
Synthesis of compound 3.117 
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(S)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid and (S)-2-amino-4- 
methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-cyclohexyl-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran- 
3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxopro
pan -2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.117 is obtained. 
Yield is 40.3%. 
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Synthesis of compound 3.118 
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(S)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-cyclopropyl-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran- 
3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo 
propan- 2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.118 is obtained. 
Yield is 30.9%. 
Synthesis of compound 3.119 
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(S)-2-((tert-butoxycarbonyl)amino)-3-cyclopentylpropanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-cyclopentyl-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran 
-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1–oxo 
propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.119 is obtained. 
Yield is 40.2%. 
Synthesis of compound 3.120 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(4-((cyclohexyloxy)carbonyl)phenyl)propanoic 
acid and (S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3 -((S)-2-oxo 
pyrrolidin-3-yl)propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA 
is added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to 
the solution. The solution is washed by NaHCO3 and brine. The organic layer is collected 
and dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
Cyclohexyl 4-((S)-2-((tert-butoxycarbonyl)amino)-3-(((S)-4-methyl-1-oxo-1-(((S,E)-1 
-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2
-yl) amino)-3-oxopropyl)benzoate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.120 is 
obtained. Yield is 32.8%. 
 
Synthesis of compound 3.121 
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(S)-3-(4-acetylphenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-(4-acetylphenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl )amino)-1- 
oxopropan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.121 is 
obtained. Yield is 41.1% 
Synthesis of compound 3.122 
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(2S,3S)-2-((tert-butoxycarbonyl)amino)-3-hydroxybutanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((2S,3S)-3-hydroxy-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran- 
3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxobut
an-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF 
at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.122 is obtained. Yield is 
39.2%. 
Synthesis of compound 3.123 
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O
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(2S,3R)-2-((tert-butoxycarbonyl)amino)-3-methylpentanoic acid and (S)-2-amino-4 
-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2
-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((2S,3R)-3-methyl-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran 
-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxope
ntan -2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.123 is obtained. 
Yield is 45.1%. 
Synthesis of compound 3.124 
H
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(S)-2-((tert-butoxycarbonyl)amino)-4,4,4-trifluorobutanoic acid and (S)-2-amino- 
4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl) 
propan-2-yl) pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
 169 
 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-4,4,4-trifluoro-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3 
(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino )-1-oxobuta
n-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF 
at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.124 is obtained. Yield is 
64.1%. 
Synthesis of compound 3.125 
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(S)-2-((tert-butoxycarbonyl)amino)-2-(2,3-dihydro-1H-inden-2-yl)acetic acid and (S)-2- 
amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl) 
propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
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Tert-butyl((S)-1-(2,3-dihydro-1H-inden-2-yl)-2-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxo
dihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl) 
amino)-2-oxoethyl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.125 is 
obtained. Yield is 27.6%. 
Synthesis of compound 3.126 
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(S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid and (S)-2-amino-4- 
methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl) pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3,3-dimethyl-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3 
(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxobuta
n-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
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removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF 
at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.126 is obtained. Yield is 
30.6%. 
Synthesis of compound 3.127 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(4-phenoxyphenyl)propanoic acid and (S)-2-amin 
o-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(4)phenoxypheny
l)propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. 
After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in 
DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 
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30 mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The 
organic layer is collected and dried by Na2SO4. After removal of solvent, the residue is 
purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.127 is obtained. 
Yield is 52.3%. 
Synthesis of compound 3.128 
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(S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetic acid and (S)-2-amino-4-methyl 
-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl) 
pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is added 
slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent,the residue is used in next step directly. 
Tert-butyl ((S)-1-cyclohexyl-2-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3 
(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-2-oxoethyl) 
carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After removal 
of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF at 0 °C. 
DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 mL EA is 
added to the solution. The solution is washed by NaHCO3 and brine. The organic layer is 
collected and dried by Na2SO4. After removal of solvent, the residue is purified by HPLC 
(C18, reverse phase, 10-90%, ACN/H2O). Compound 3.128 is obtained. Yield is 39.4%. 
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Synthesis of compound 3.129 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(3-chlorophenyl)propanoic acid and (S)-2-amino 
-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan
-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent,the residue is used in next step directly. 
Tert-butyl ((S)-3-(3-chlorophenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-o
xo propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.129 is 
obtained. Yield is 56.6%. 
Synthesis of compound 3.130 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(3-methoxyphenyl)propanoic acid and (S)-2- 
amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl) 
propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent,the residue is used in next step directly. 
Tert-butyl ((S)-3-(3-methoxyphenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl) 
amino)-1-oxo propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction 
is complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.130 is 
obtained. Yield is 38.4%. 
Synthesis of compound 3.131 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(3-isopropoxyphenyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-(3-isopropoxyphenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxo 
dihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl) 
amino)-1-oxopropan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction 
is complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC C18, reverse phase, 10-90%, ACN/H2O). Compound 3.131 is 
obtained. Yield is 45.6%. 
Synthesis of compound 3.132 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(2-methoxyphenyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl) propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl ((S)-3-(2-methoxyphenyl)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydro 
furan-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl) 
amino)-1-oxo propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction 
is complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent,the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.132 is 
obtained. Yield is 27.1%. 
Synthesis of compound 3.133 
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(S)-2-((tert-butoxycarbonyl)amino)-3-(o-tolyl)propanoic acid and 
(S)-2-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin
-3-yl)propan-2-yl) pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. 
T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(o-tolyl)propan-2-
yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is complete. After 
removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is dissolved in DMF 
at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete after 20 mins. 30 
mL EA is added to the solution. The solution is washed by NaHCO3 and brine. The organic 
layer is collected and dried by Na2SO4. After removal of solvent, the residue is purified by 
HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.133 is obtained. Yield is 
50.3%. 
Synthesis of compound 3.134 
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Tert-butyl((2S)-4-(tert-butylamino)-3-hydroxy-4-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-
2-yl)carbamate is dissolved in HCl/dioxane. After stirring for 15 mins, the reaction is 
complete. The solvent is taken off and the residue is dried by vacuum for 2 hours. 
(S)-methyl-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(dimethylamino)propanamido)-4-
methylpentanoate is dissolved in THF/MeOH/H2O. LiOH is added. After 30 mins, the 
reaction is complete. The solution is concentrated and the residue is dried by vacuum for 2 
hours. The residues are dissolved in DMF at 0 °C. DIPEA is added. T3P solution is added 
slowly. After 20 mins, the reaction is complete. The mixture is diluted by 30 mL EA and 
washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is used in next step directly. 
Benzyl((4S,7S,10S)-11-hydroxy-7-isobutyl-2,14,14-trimethyl-5,8,12-trioxo-10-(((S)-2-o
xopyrrolidin-3-yl)methyl)-2,6,9,13-tetraazapentadecan-4-yl)carbamate is dissolved in DCM. 
Dess-martin reagent is added. The mixture is sonicated for 5 mins. After stirred for 1 hours, 
the reaction is complete (confirmed by LCMS basic method). The whole mixture is loaded 
onto the column (silica gel, normal phase) and purified by 2-Propanol/DSM, 0-60%. 
Compound 3.134 is obtained. Yield is 19.21%. 
Synthesis of compound 3.135 
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(2S)-2-Amino-N-((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxopyrrolidin-3-y
l)butan-2-yl)-4-methylpentanamide, Hydrochloride dissolved in DMF at 0 °C with 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-(trifluoromethyl)piperidin-1-yl)propanoic acid. 
DIPEA is added. T3P solution is added slowly. After 20 mins, the reaction is complete. The 
mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, the residue is used in next step directly.  
Benzyl((2S)-1-(((2S)-1-(((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxo 
pyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-(4-(trifluoro 
methyl)piperidin-1-yl)propan-2-yl)carbamatee is in DCM. Dess-martdissolved in reagent is 
added. The mixture is sonicated for 3 mins. After stirred for 1 hour, the reaction is complete. 
The mixture is loaded onto the column directly and purified by column (silica gel, normal 
phase, 0-60%, 2-propanol/DCM). Compound 3.135 is obtained. Yield is 72.8%. 
Synthesis of compound 3.136 
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(2S)-2-amino-N-((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxopyrrolidin-3-yl
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)butan-2-yl)-4-methylpentanamide, Hydrochloride dissolved in DMF at 0 °C with (S)-2- 
(((benzyloxy)carbonyl)amino)-3-(4-methylpiperazin-1-yl)propanoic acid. DIPEA is added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is used in next step directly. 
Benzyl((2S)-1-(((2S)-1-(((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxo 
pyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(4-methylpiperazin-
1-yl) -1-oxopropan-2-yl)carbamate is in DCM. Dess-martdissolved in reagent is added. The 
mixture is sonicated for 3 mins. After stirred for 1 hour, the reaction is complete. The mixture 
is loaded onto the column directly and purified by column (silica gel, normal phase, 0-100%, 
MeOH(TEA)/DCM). Compound 3.136 is obtained. Yield is 83%. 
 
 
 
 
Synthesis of compound 3.137 
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(2S)-2-amino-N-((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxopyrrolidin-3-yl
)butan-2-yl)-4-methylpentanamide, Hydrochloride dissolved in DMF at 0 °C with 
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2-Benzyloxycarbonylamino-3-(4,4-difluoro-piperidin-1-yl)-propionic acid. DIPEA is added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is used in next step directly. 
(2-(4,4-Difluoro-piperidin-1-yl)-1-{1-[2-hydroxy-2-isopropylcarbamoyl-1-(2-oxo-pyrrol
idin-3-ylmethyl)-ethylcarbamoyl]-3-methyl-butylcarbamoyl}-ethyl)-carbamic acid benzyl 
ester is in DCM. Dess-martdissolved in reagent is added. The mixture is sonicated for 3 mins. 
After stirred for 1 hour, the reaction is complete. The mixture is loaded onto the column 
directly and purified by column (silica gel, normal phase, 0-100%, MeOH(TEA)/DCM). 
Compound 3.137 is obtained. Yield is 63%. 
Synthesis of compound 3.138 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-morpholinopropanoate is dissolved in 
HCl/dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and 
the residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0 °C. K2CO3 
is added. Cbz-Cl is added dropwised. After 30 mins, the reaction is complete. The mixture is 
diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by column (normal phase, silica gel, 
0-100% EA/HX). 
Benzyl((2S)-1-(((2S)-1-(((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxo 
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pyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-morpholino-1-oxo 
propan -2-yl)carbamatee is in DCM. Dess-martdissolved in reagent is added. The mixture is 
sonicated for 3 mins. After stirred for 1 hour, the reaction is complete. The mixture is loaded 
onto the column directly and purified by column (silica gel, normal phase, 0-60%, 
2-propanol/DCM). ). Compound 3.138 is obtained. Yield is 58.2%. 
Synthesis of compound 3.139 
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(2S)-2-amino-N-((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxopyrrolidin-3- 
yl)butan-2-yl)-4-methylpentanamide, Hydrochloride dissolved in DMF at 0 °C with 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(piperidin-1-yl)propanoic acid. DIPEA is added. T3P 
solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted by 30 
mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is used in next step directly. 
Benzyl((2S)-1-(((2S)-1-(((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S)-2-oxo 
pyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-(piperidin-1-y
l) propan-2-yl)carbamate is in DCM. Dess-martdissolved in reagent is added. The mixture is 
sonicated for 3 mins. After stirred for 1 hour, the reaction is complete. The mixture is loaded 
onto the column directly and purified by column (silica gel, normal phase, 0-60%, 
2-propanol/DCM). Compound 3.139 is obtained. Yield is 13.38%. 
Synthesis of compound 3.140, 3.141 
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(R)-2-benzyl-3-((tert-butoxycarbonyl)amino)propanoic acid, (2R)-4,4-dimethyl-N- 
((2S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-(2-oxopyrrolidin-3-yl)propan-2-yl)pyrrolidin
e-2-carboxamide, Hydrochloride are dissolved in DMF at 0 °C, DIEA is added. T3P is added 
slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic 
layer is dried by Na2SO4. After removal of solvent, white solid 3.151 is collected as crude 
product for next step. 
Tert-butyl ((2R)-2-benzyl-3-((2R)-4,4-dimethyl-2-(((2S,E)-1-(2-oxodihydrofuran- 3(2H) 
-ylidene)-3-(2-oxopyrrolidin-3-yl)propan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-oxopropyl)carba
mate is dissolved in HCl/dioxane. After 20 mins, the reaction is complete. After removal of 
solvent, the crude solid 3.152 is collected for next step directly. 
(R)-1-((R)-3-amino-2-benzylpropanoyl)-4,4-dimethyl-N-((S,E)-1-(2-oxodihydrofuran-3(
2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pyrrolidine-2-carboxamide is dissolved 
in DMF at 0 °C. DIEA is added. 5-methylisoxazole-3-carbonyl chloride is added slowly. 
After 20 mins, the reaction is complete. The solution is diluted by 30 mL EA and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O).The product 3.140 is a 
mixture of two diastereomers (3:1) which is confirmed by NMR and LCMS (long method). 
Yield is 39%. 
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(R)-1-((R)-3-amino-2-benzylpropanoyl)-4,4-dimethyl-N-((S,E)-1-(2-oxodihydrofuran-3(
2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)pyrrolidine-2-carboxamide is dissolved 
in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. After 20 mins, the reaction is 
complete. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4. The organic layer is dried by Na2SO4. After removal of 
solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O).The 
product 3.141 is a mixture of 1:3 diastereomer. Yield is 38%. 
Synthesis of compound 3.142 
H
N
O
H
N
N
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O
H
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H
F
O
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(R)-2-benzyl-3-((tert-butoxycarbonyl)amino)propanoic acid, (S)-2-amino-3-(4-fluoro 
phenyl)-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2
-yl) propanamide, Hydrochloride are dissolved in DMF at 0 °C, DIEA is added. T3P is added 
slowly. The solution is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic 
layer is dried by Na2SO4. After removal of solvent, white solid is collected as crude product 
3.153 for next step. 
Tert-butyl((R)-2-benzyl-3-(((S)-3-(4-fluorophenyl)-1-oxo-1-(((S,E)-1-(2-oxodihydrofura
n-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)amino)-3 
-oxopropyl)carbamatee is dissolved in HCl/dioxane. After 20 mins, the reaction is complete. 
After removal of solvent, the crude solid 3.154 is collected for next step directly. 
(R)-3-amino-2-benzyl-N-((S)-3-(4-fluorophenyl)-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-
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3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)propanamide, 
Hydrochloride is dissolved in DMF at 0 °C. DIEA is added. 5-methylisoxazole-3-carbonyl 
chloridel is added slowly. After 20 mins, the reaction is complete. The solution is diluted by 
30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is purified by HPLC (C18, reverse phase, 10-90%,ACN/H2O). 
Compound 3.142 is obtained. 
Synthesis of compound 3.143 
N
O NH
NH
O
N
H
O
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H
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O
N
H
F
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5-methylisoxazole-3-carboxylic acid dissolved in DMF at 0 °C. (S)-methyl 
2-aminopropanoate, Hydrochloride is added. DIEA is added. T3P is added slowly. After 20 
mins, the reaction is complete. The mixture is diluted by 30 mL EA and washed by NaHCO3 
and brine. The organic layer is dried by Na2SO4. After removal of solvent, the residue 3.146 
is used in next step directly. 
(S)-methyl-2-(5-methylisoxazole-3-carboxamido)propanoate is dissolved in THF/H2O 
/MeOH. LiOH is added. After 45 mins, the reaction is complete. After filtration, the solution 
is concentrated by dried by vacuum. The residue 3.147 is directly used in next step. 
(S)-2-(5-methylisoxazole-3-carboxamido)propanoic acid dissolved in DMF at 0 °C. 
(S)-methyl 2-amino-3-(4-fluorophenyl)propanoate, Hydrochloride is added. DIEA is added. 
T3P is added slowly. After 20 mins, the reaction is complete. The mixture is diluted by 30 mL 
EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal 
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of solvent, the residue 3.148 is used in next step directly. 
(S)-Methyl-3-(4-fluorophenyl)-2-((S)-2-(5-methylisoxazole-3-carboxamido) 
propanamido) propanoate is dissolved in THF/H2O/MeOH. LiOH is added. After 90 mins, 
the reaction is complete. After filtration, the solution is concentrated by dried by vacuum. The 
residue 3.149 is directly used in next step. 
(S)-1-(tert-butoxycarbonyl)-4, 4-dimethylpyrrolidine-2-carboxylic acid is dissolved in 
DMF at 0 °C. (3S)-3-amino-2-hydroxy-N-isopropyl-4-((S)-2-oxopyrrolidin-3-yl) butanamide, 
Hydrochloride and DIPEA are added. T3P solution is added slowly. After 20 mins, the 
reaction is complete. The mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. 
The organic layer is dried by Na2SO4. After removal of solvent, the residue is used in next 
step directly. 
(2S)-tert-butyl 2-(((2S)-3-hydroxy-4-(isopropylamino)-4-oxo-1-((S) -2-oxopyrrolidin 
-3-yl)butan-2-yl)carbamoyl)-4,4-dimethylpyrrolidine-1-carboxylate is dissolved in 
HCl/dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and 
the residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0°C. 
(S)-3-(4-fluorophenyl) -2-((S)-2-(5-methylisoxazole-3-carboxamido) propanamido) and 
DIPEA are added. T3P solution is added slowly. After 20 mins, the reaction is complete. The 
mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. The organic layer is 
dried by Na2SO4. After removal of solvent, the residue 3.150 is used in next step directly. 
N-((2S)-1-(((2S)-3-(4-fluorophenyl)-1-((2S)-2-(((2S)-3-hydroxy-4-(isopropylamino)-4-o
xo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)carbamoyl)-4,4-dimethylpyrrolidin-1-yl)-1-oxopro
pan-2-yl) amino)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide is dissolved in DCM. 
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Dess-martin reagent is added. The mixture is sonicated for 2 mins. Then the reaction is stirred 
in room temperature for 40 mins. The reaction is monitored by LCMS. After it's complete, the 
mixture is directly loaded onto a silica columm and purified by acetone/DCM, 0-50%. 3.143 
is obtained. Yield is 49%. 
Synthesis of compound 3.144 
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Methyl 2-amino-3-methylbutanoate, Hydrochloride is dissolved in DMF at 0 °C with 
DIPEA and 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid. T3P is added slowly. 
After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, it is 
used in next step directly. 
Methyl 2-(2-((tert-butoxycarbonyl)amino)-2-methylpropanamido)-3-methylbutanoate is 
dissolved in HCl/dioxane. After 20 mins, the reaction is complete. After removal of solvent, 
the residue 3.154 is dried by vacuum for 1 hour and directly used in next step. 
The solid is dissolved in DMF with 5-methylisoxazole-3-carboxylic acid and DIPEA at 
0 °C. T3P is added slowly. After 30mins, the reaction is complete. The solution is diluted by 
30 mL EA and washed by NaHCO3 and brine. Aqueous layer is extract by 15 mL EA.The 
organic layers are combined and dried by Na2SO4. After concentrated, the residue 3.155 is 
used in next step directly. 
Methyl 3-methyl-2-(2-methyl-2-(5-methylisoxazole-3-carboxamido) propanamido) 
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butanoate is dissolved in THF/MeOH/Water. LiOH is added. After stirred for 1 hour, the 
reaction is complete. The mixture is filtered. After removal of solvent, the residue 3.156 is 
directly used in next step. 
(E)-Benzyl-4-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-5-(2-oxo 
pyrrolidin-3-yl) pent-2-enoate is dissolved in HCl/dioxane. After stirred for 10 mins, the 
reaction is complete. The mixture is concentrated by dried by vacuum for 2 hours. 
The residue is dissolved in DMF at 0 °C with DIPEA and 3-methyl-2-(2-methyl 
-2-(5-methylisoxazole-3-carboxamido) propanamido) butanoic acid. T3P is added slowly. 
After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, it is 
purified by HPLC (reverse phase, C18, 10-90%, ACN/H2O). Compound 3.144 is obtained. 
Yield is 31%. 
Synthesis of compound 3.145 
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Under N2 protection, all reactants and DMA are added to the reacion vessel. The 
reaction is sealed and warmed up to 80°C. The color is brown (not blue). The reaction is kept 
stirring for 2 days. LCMS shows the reaction is complete. The reaction is cooled to room 
temperature. 10 mL EA and 6 mL water are added to the mixture. The pH is adjusted to 2-3 
by concentrated HCl. The water layer is extracted 5 time by 20 mL EA (each time) until the 
organic layer is almost colorless. The organic layers are combined and dried by Na2SO4. 
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After removal of solvent, the residue 3.157 is purified by column (normal phase, silica gel, 
0-100%, EA/HX). 
(S)-2-(phenylamino)propanoic acid and (S)-methyl 2-amino-3-methylbutanoate, 
Hydrochloride are dissolved in DMF at 0 °C. DIPEA is added. T3P solution is added slowly. 
After 15 mins the reaction is complete. The mixture is diluted by 30 mL EA and washed by 
NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of solvent, the 
residue 3.158 is used in next step directly. 
(E)-benzyl4-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-5-(2-oxopyrroli
din-3-yl) pent-2-enoate is dissolved in HCl/dioxane. The reaction is stirred for 20 mins. Afte 
removal of solvent, the residue is dried by vacuum for 2 hours. 
(S)-2-(phenylamino)propanoic acid and residue are dissolved in DMF at 0 °C. DIPEA is 
added. T3P is added slowly. After 10 mins, the reaction is complete. The mixture is diluted by 
30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is used in next step directly. 
(S)-Methyl 3-methyl-2-((S)-2-(phenylamino)propanamido)butanoate is dissolved in 
THF /MeOH / Water. LiOH is added. After stirred for 1 hour, the reaction is complete. After 
removal of solvent, the residue 3.159 is used in next step directly. 
(6S, 9S, E)-Benzyl 9-isobutyl-6-isopropyl-2, 2-dimethyl-4, 7, 10-trioxo-12- ((2-oxo 
pyrrolidin-3-yl) methyl)-3-oxa-5,8,11-triazapentadec-13-en-15-oate is dissolved in HCl/ 
dioxane. After stirring for 15 mins, the reaction is complete. The solvent is taken off and the 
residue is dried by vacuum for 2 hours. The residue is dissolved in DMF at 0 °C. 
(S)-3-methyl-2-((S)-2-(phenylamino)propanamido)butanoic acid and DIPEA are added. T3P 
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solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted by 30 
mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is purified by HPLC (reverse phase, C18, ACN/H2O, 
0-80%).Compound 3.145 is obtained. Yield is 45%. 
Synthesis of compound 3.160 
CbzHN
N
O
O
OH
 
(S)-benzyl (2-oxooxetan-3-yl)carbamate is dissolved in dry ACN under N2 protection. 
4-(trimethylsilyl)morpholine solution in dry ACN is added. The reaction is stirred in room 
temperature for 6 hours. LCMS shows two peaks which have identical molecular weight. 
After LCMS shows the reaction is complete, it is quenched by HCl (0.5 M, 2 mL). After 
stirred for 20 mins, the mixture is concentrated and the residue is purified by HPLC (C18, 
reverse phase, 0-75%, ACN/H2O). Two fractions are collected. Compound 3.160 is obtained. 
Yield is 55.6%. 
Synthesis of compound 3.161 
CbzHN
N
O
OH
 
Piperdine is dissolved in dry ACN under N2 protection. (Z)-trimethylsilyl 
N-(trimethylsilyl)acetimidate is added. The reaction is stirred in room temperature for 2-3 
hours. Then (S)-benzyl (2-oxooxetan-3-yl)carbamate is added to the reaction. After 4 hours, 
LCMS shows two peaks which have identical molecular weight. The reaction is quenched by 
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HCl (0.5 M, 2 mL). After stirred for 20 mins, the mixture is concentrated and the residue is 
purified by HPLC (C18, reverse phase, 0-75%, ACN/H2O). Two fractions are collected. 
(S)-benzyl (2-oxooxetan-3-yl)carbamate is dissolved in dry ACN under N2 protection. 
1-(trimethylsilyl)piperidine solution in dry ACN is added. The reaction is stirred in room 
temperature for 6 hours. After LCMS shows the reaction is complete, it is quenched by HCl 
(0.5 M, 2 mL). After stirred for 20 mins, the mixture is concentrated and the residue is 
purified by HPLC (C18, reverse phase, 0-75%, ACN/H2O). Compound 3.161 is obtained. 
Yield is 63.4%. 
 
Synthesis of compound 3.162 
CbzHN
N
O
OH
CF3
 
Piperidine is dissolved in dry ACN under N2 protection. (Z)-trimethylsilyl 
N-(trimethylsilyl)acetimidate is added. The reaction is stirred in room temperature for 2-3 
hours. Then (S)-benzyl (2-oxooxetan-3-yl)carbamate is added to the reaction. After 4 hours, 
LCMS shows two peaks which have identical molecular weight. The reaction is quenched by 
HCl (0.5 M, 2 mL). After stirred for 20 mins, the mixture is concentrated and the residue is 
purified by HPLC (C18, reverse phase, 0-75%, ACN/H2O). Two fractions are collected. 
Compound 3.162 is obtained. Yield is 39.2%. 
Synthesis of compound 3.163 
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1-Methylpiperazine is dissolved in dry ACN under N2 protection. (Z)-trimethylsilyl 
N-(trimethylsilyl)acetimidate is added. The reaction is stirred in room temperature for 2-3 
hours. Then (S)-benzyl (2-oxooxetan-3-yl)carbamate is added to the reaction. After 4 hours, 
the reaction is quenched by HCl (0.5 M, 2 mL). After stirred for 20 mins, the mixture is 
concentrated and the residue is purified by HPLC (C18, reverse phase, 0-75%, ACN/H2O). 
Compound 3.163 is obtained. Yield is 47.5%. 
 
 
Synthesis of compound 3.168 
H2N
OH
O
O
O
 
(2R,3S)-benzyl 6-oxo-2,3-diphenylmorpholine-4-carboxylate is dissolved in 10 mL dry 
THF. Ultrasonication is used to help solid dissolve. The solution is cooled to -78 °C by dry 
ice/acetone. LiHMDS is added dropwised. The mixture is kept for 10 mins under N2 
protection. Then 5-(bromomethyl)benzo[d][1,3]dioxole in 0.5 mL dry THF solution is added 
to the reaction. The reaction is kept under -78 °C for 30 mins. Then the temperature is 
increased to -41°C by dry ice/ACN. After 30 mins, the temperature is increased to -15°C by 
ice/salt. After 20mins, the reaction is complete. 10 mL water is added to the reaction to 
quench it. The solution is diluted by 30 mL EA and washed by brine. The organic layer is 
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dried by Na2SO4. After removal of solvent, the residue is purified by column (24 g, silica gel, 
0-80% EA/HX).  
(3S,5S,6R)-Benzyl-3-(benzo[d][1,3]dioxol-5-ylmethyl)-2-oxo-5,6-diphenylmorpholine-
4-carboxylate is dissolved in THF/MeOH. PdCl2 is added. The reaction is carried under 50 
psi H2 for over night. The reaction stops in the intermediate step (de-Cbz). Another 0.3 eq 
PdCl2 is added. After one day, the reaction doesn't change much. The Pd is filtered. Pd/C 
(30%) is added. After 2 days, the reaction is complete. The solution is acidified by HCl in 
dioxane. After removal of solvent, the residue is rinsed by ether. The solid is collected by 
filtration. The crude product is directly used for next step. Compound 3.168 is obtained. Two 
steps yield is 61.8%. 
Synthesis of compound 3.169 
H2N
OH
O
 
(2R,3S)-benzyl 6-oxo-2,3-diphenylmorpholine-4-carboxylate is dissolved in 10 mL dry 
THF. Ultrasonication is used to help solid dissolve. The solution is cooled to -78 °C by dry 
ice/acetone. LiHMDS is added dropwised. The mixture is kept for 10 mins under N2 
protection. Then3-(bromomethyl)-1,1'-biphenyl in 0.5 mL dry THF solution is added to the 
reaction. The reaction is kept under -78 °C for 30 mins. Then the temperature is increased to 
-41°C by dry ice/ACN. After 30 mins, the temperature is increased to - 15°C by ice/salt. After 
30mins, the reaction is complete. 10 mL water is added to the reaction to quench it. The 
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solution is diluted by 30 mL EA and washed by brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is purified by column (24 g, silica gel, 0-60% EA/HX). 
(3S,5S,6R)-Benzyl-3-([1,1'-biphenyl]-3-ylmethyl)-2-oxo-5,6-diphenylmorpholine-4-car
boxylate is dissolved in MeOH/THF. Pd/C is added. The reaction is carried under 50 psi H2 
for 24 hours. The solution is filtered by celite. Filter cake is washed by methanol. After 
removal of solvent, the residue is directly used in next step. Compound 3.169 is obtained. 
Two steps yield is 57.3%. 
 
 
 
Synthesis of compound 3.170 
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(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(3-phenoxyphenyl)propanoate is dissolved 
in THF/MeOH/Water. LiOH is added. After 15 mins, the reaction is complete. The solution is 
diluted by 30 mL EA and washed by HCl (1M) and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is used for next step directly. 
(S)-2-((tert-butoxycarbonyl)amino)-3-(3-phenoxyphenyl)propanoic acid and (S)-2 
-amino-4-methyl-N-((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3-((S)-2-oxopyrrolidin-3-yl) 
propan-2-yl)pentanamide, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P 
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is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. 
The solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, the residue is used in next step directly. 
Tert-butyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-1-(2-oxodihydrofuran-3(2H)-ylidene)-3
-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxo-3-(3-phenoxy 
phenyl )propan-2-yl)carbamate is dissolved in HCl/dioxane. After 15 mins, the reaction is 
complete. After removal of solvent, ther residue is dried by vacuum for 30 mins. Then it is 
dissolved in DMF at 0 °C. DIEA is added. Cbz-Cl is added slowly. The reaction is complete 
after 20 mins. 30 mL EA is added to the solution. The solution is washed by NaHCO3 and 
brine. The organic layer is collected and dried by Na2SO4. After removal of solvent, the 
residue is purified by HPLC (C18, reverse phase, 10-90%, ACN/H2O). Compound 3.170 is 
obtained. Yield is 40.9%. 
Synthesis of compound 3.171 
BocHN COOMe
O
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
1-bromo-3-phenoxybenzene in DMF (1 mL) is added by syringe. The reaction is warmed up 
to 50 °C for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to the 
solution. The mixture is washed by NaHCO3 and brine. The organic layer is dried by 
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Na2SO4. After removal of solvent, the residue is purified by column (silica gel, normal phase, 
0-100%, EA/HX). Compound 3.171 is obtained. Yield is 87%. 
Synthesis of compound 3.173 
BocHN
OH
O
 
Tf2O is added to pyridine in pentane solution at 0 °C. It forms white/pink solid. After 
stirred for 1 hour, cyclopent-3-en-1-ylmethanol in pentane solution is added to the reaction 
slowly. The reaction is kept for another 1.5 hours in ice bath. Then the mixture is filtered by 4 
g aluminum oxide and washed by 20 mL pentane. After removal of solvent, colorless oil is 
collected as product. NMR shows clean. 
(2R,3S)-tert-butyl 6-oxo-2,3-diphenylmorpholine-4-carboxylate is dissolved in 
THF/HMPA and cooled to -78 °C. NaHMDS solution is added and kept for 30 mins. 
Cyclopent-3-en-1-ylmethyl trifluoromethanesulfonate is dissolved in 3 mL THF and added 
dropwised to the reaction. The reaction is kept for 2 hours. Then it is warmed up to room 
temperature. The mixture is diluted by 30 mL EA and washed by NaHCO3 and brine. The 
organic layer is dried by Na2SO4 and purified by column (normal phase, silica gel, 0- 60%, 
EA/HX). 
Liquid ammonia is condensed by dryice/acetone.The three neck flask is cooled to -78 °C 
and protected by N2. After about 20 mL liquid ammonia is collected, lithium metal is added. 
The solution turns dark blue. Let the mixture stir for 30 mins. The solution of 
(3S,5S,6R)-tert-butyl 3-(cyclopent-3-en-1-ylmethyl)-2-oxo-5,6-diphenylmorpholine 
-4-carboxylate in THF and ethanol is added. The reaction is kept under -78 °C for 2 hours. 
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LCMS shows the reaction is complete. 5 mL methanol is slowly added to quench the reaction. 
Then the mixture is acidified by diluted HCl (1 M) to pH 2. The solution is extracted by EA 
(20 mL) twice. The organic layer is dried by Na2SO4. After removal of solvent, the residue 
3.173 is directly used in next step. Three steps yield is 45.3%. 
Synthesis of compound 3.174 
BocHN COOMe
N
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
2-bromoquinoline in DMF (1 mL) is added by syringe. The reaction is warmed up to 50 °C 
for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to the solution. 
The mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is purified by column (silica gel, normal phase, 0-90%, 
EA/HX). Compound 3.174 is obtained. Yield is 64.7%. 
Synthesis of compound 3.175 
BocHN COOMe
N
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
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3-bromoquinoline in DMF (1 mL) is added by syringe. The reaction is warmed up to 50 °C 
for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to the solution. 
The mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is purified by column (silica gel, normal phase, 0-90%, 
EA/HX). Compound 3.175 is obtained. Yield is 75%. 
Synthesis of compound 3.176 
BocHN COOMe
N
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
6-bromoquinoline in DMF (1 mL) is added by syringe. The reaction is warmed up to 50 °C 
for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to the solution. 
The mixture is washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After 
removal of solvent, the residue is purified by column (silica gel, normal phase, 0-100%, 
EA/HX). Compound 3.176 is obtained. Yield is 49%. 
Synthesis of compound 3.177 
BocHN COOMe
O
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
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colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
1-bromo-3-methoxybenzene in DMF (1 mL) is added by syringe. The reaction is warmed up 
to 50 °C for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to the 
solution. The mixture is washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by column (silica gel, normal phase, 
0-100%, EA/HX). Compound 3.177 is obtained. Yield is 81%. 
 
 
Synthesis of compound 3.178 
BocHN COOMe
O
 
Zinc powder is pre-activated. Zn is added to a two neck round bottom flask with N2 
protection. 1.5 mL DMF is added. I2 is added. The color of solution becomes purple then 
colorless. Boc-Iodoalanine-OH is added. After 10 mins, the mixture of Pd2(dba)3, SPhos and 
1-bromo-3-isopropoxybenzene in DMF (1 mL) is added by syringe. The reaction is warmed 
up to 50 °C for 3 hours. Then the reaction is cool to room temperature. 30 mL EA is added to 
the solution. The mixture is washed by NaHCO3 and brine. The organic layer is dried by 
Na2SO4. After removal of solvent, the residue is purified by column (silica gel, normal phase, 
0-100%, EA/HX). Compound 3.178 is obtained. Yield is 88%. 
Synthesis of compound 3.179 
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FmocHN COOH
NH
 
(S)-2-((tert-butoxycarbonyl)amino)-3-(pyridin-4-yl)propanoic acid is dissolved in ethanol and 
water. The solution is ajusted to pH 2-3 to make the solid completely dissolved. Pd-C is 
added carefully. The reaction is carried under 50-60 psi H2. After over night, the reaction is 
complete. The Pd/C is filtered by celite. The solution is ajusted to pH 10-11 by NH3-H2O. 
Solvent is completely removed. White solid 3.179 is collected as product for next step. 
 
 
Synthesis of compound 3.180 
N N
H
COOEt
 
Ethyl acrylate is dissolved in heptane/toluene at 0 °C with N2 protection. (diazomethyl) 
trimethylsilane is added. Then the solution is warmed up to room temperature. After 1 hour, 
the reaction is complete. The mixture 3.180 is concentrated at 30 °C and directly used in next 
step. 
Synthesis of compound 3.181 
N
H
H
N
F
O
N
H
H
N
O
O
O
O
O
O
 
(S)-2-((S)-2-(((benzyloxy) carbonyl) amino)-3-methylbutanamido)-3-(4-fluorophenyl) 
propanoic acid and (S)-3-((S,E)-2-amino-3 -(5,5-dimethyl-2-oxodihydrofuran-3(2H)-ylidene) 
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propyl)pyrrolidin-2-one, Hydrochloride are dissolved in DMF at 0 °C. DIEA is added. T3P is 
added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the solution. The 
solution is washed by NaHCO3 and brine. The organic layer is collected and dried by 
Na2SO4. After removal of solvent, Compound 3.181 is purified by HPLC (C18, reverse 
phase, 10-90%, ACN/H2O).Yield is 21.7%. 
 
 
 
Synthesis of compound 3.182 
N
H
H
N
F
N
H
H
NO
O
O
O
O
O
O
 
(S)-3-((S,E)-2-amino-3-(2-oxodihydro-2H-pyran-3(4H)-ylidene)propyl)pyrrolidin-2-one, 
Hydrochloride is dissolved in DMF at 0 °C with DIPEA and (S)-2-((S)-2- 
(((benzyloxy)carbonyl) amino)-3-methylbutanamido)-3-(4-fluorophenyl)propanoic acid. T3P 
is added slowly. After 15 mins, the reaction is complete. The mixture is diluted by EA (30 mL) 
and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. After removal of 
solvent, Compound 3.182 is purified by HPLC (reverse phase, C18, 10-90%, ACN/H2O). 
Yield is 41%. 
Synthesis of compound 3.183 
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N
O
O
N
H
H
N
O
O
O
N
H
F
O
 
(S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid and (S)-methyl 
2,5-dihydro-1H-pyrrole-2-carboxylate, Hydrochloride are dissolved in DMF at 0 °C. DIEA is 
added. T3P is added slowly. The reaction is complete after 20 mins. 30 mL EA is added to the 
solution. The solution is washed by NaHCO3 and brine. The organic layer is collected and 
dried by Na2SO4. After removal of solvent, the residue 3.75 is used in next step directly. 
(S)-Methyl-1-((S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoyl)-2,5-di
hydro-1H-pyrrole-2-carboxylate is dissolved in THF/Methanol/Water. LiOH is added. After 
1hour, the reaction is complete. After removal of solvent, the residue 3.80 is dried by vacuum 
for over night and directly used in next step. 
(S)-1-((S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoyl)-2,5-dihydro-1
H-pyrrole-2-carboxylic acid is dissolved in DMF at 0 °C. (S)-3-((S,E)-2-amino-3-(2-oxo 
dihydrofuran-3(2H)-ylidene)propyl)pyrrolidin-2-one, Hydrochloride and DIPEA are added. 
T3P solution is added slowly. After 20 mins, the reaction is complete. The mixture is diluted 
by 30 mL EA and washed by NaHCO3 and brine. The organic layer is dried by Na2SO4. 
After removal of solvent, the residue is purified by HPLC (reverse phase, C18, 10-90%, 
ACN/H2O). Compound 3.183 is obtained. Yield is 37.3%. 
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